diana shu-lian chow, ph.d. office address phone & e...

D. S-L. Chow

5/9/2012 1

Curriculum Vitae

DIANA SHU-LIAN CHOW, Ph.D. OFFICE ADDRESS Department of Pharmacological and Pharmaceutical Sciences PHONE & E-MAIL: University of Houston Texas Medical Center 1441 Moursund Street Houston, Texas 77030 Tel: (713) 795-8308 Fax: (713)-795-8305 e-mail: [email protected] PRESENT POSITION: Professor (2009- Present)

Department of Pharmacological and Pharmaceutical Sciences (PPS), College of Pharmacy

University of Houston Director (1991-Present) Institute of Drug Education and Research (IDER) College of Pharmacy University of Houston Adjunct Associate Professor (2006-2009)

Adjunct Professor, (2009-Present) Clinical Pharmacology Training Program Baylor College of Medicine/Texas Children Hospital EXPERIENCE: Associate Professor (1993-2009)

Department of Pharmacological and Pharmaceutical Sciences (PPS) College of Pharmacy

University of Houston Adjunct Associate Professor (2002-2009) Department of Immunology M.D. Anderson Cancer Center University of Texas Visiting Associate Professor (2000-02) Department of Immunology, M.D. Anderson Cancer Center University of Texas

D. S-L. Chow

5/9/2012 2

Interim Chair (1991-93) Department of Pharmaceutics College of Pharmacy University of Houston Associate Professor (1987-93) Department of Pharmaceutics College of Pharmacy University of Houston

(In 1993, Departments of Pharmaceutics, Medicinal Chemistry and Pharmacology merged into Department of Pharmacological and Pharmaceutical Sciences)

Assistant Professor (1981-87) Department of Pharmaceutics College of Pharmacy University of Houston EDUCATION: Ph.D. Pharmacy 1981 University of British Columbia, Canada M.S. Pharmacy 1975 Ohio State University B.S. Pharmacy 1973 National Taiwan University HONORS AND AWARDS

1. Invited Lecturer, North American Clinical Trial Network (NACTN) Meeting, March 18, 2011, Toronto, Ontario, Canada

2. 2009 Inventor of the Year Award, for Parenteral Busulfan for Treatment of Malignant Disease (Patents No. 5,430,057 and 5,559,148), granted by Houston Intellectual Property Law Association (HIPLA), Houston, TX, September 2009.

3. Invited Lecturer and Session Co-Chair on Nanotechnologies

and Novel Drug Delivery Technologies, The 6th

Annual Congress of International Drug Discovery Science and Technology (IDDST), October 18-22, 2008, Beijing, China.

4. Invited Lecturer, Ehrlich II World Conference on Magic

Bullets, (for celebrating 100th

Anniversary of Nobel Prize to Paul Ehrlich, October 3, 2008, Nuremberg, Germany.

5. Invited Lecturer, North American Clinical Trial Network

(NACTN) Meeting, February 18, 2008, Texas Medical Center, Houston, TX.

D. S-L. Chow

5/9/2012 3

6. Faculty Service Excellence Award, College of Pharmacy,

University of Houston, May 2007.

7. 2006 Faculty Scholar Award in Cancer Research, American Association for Cancer Research – Minority-Serving Institution (AACR-MSI), Washington D.C., April 2006.

8. 2005 Faculty Scholar Award in Cancer Research, American

Association for Cancer Research – Minority-Serving Institution (AACR-MSI), Anaheim, California, April 2005

9. Invited Lecturer, Ehrlich I World Conference (for celebrating

Nobel Laureate Paul Ehrlich’s 150th

Birthday), September 9, 2004, Nuremberg, Germany. [Only 1,000 scientists and clinicians were invited from 84 countries.]

10. Gillson Longenbaugh Foundation Research Award, 2003-

2008.

11. Plenary Lecturer, Conference on The Camptothecins: Unfolding Their Anticancer Potential”, March 18, 2000, Ritz-Carlton Pentagon City, Arlington, Virginia.

COMMITTEES AND REVIEW PANELS FOR GOVERNMENT AND PROFESSIONAL SOCIETIS

1. Canadian Institutes of Health Research (CIHR)/ GlaxoSmithKline (GSK) Partnered Professorship Review Committee, May 2009.

2. Earmarked Research Grants, Hong Kong Research Grant

Council (RGC), March 2009.

3. Development of a Third Generation Anthrax Vaccine, RFP-NIH-NIAID-DMID-07-05, NIAID, NIH, January 11-12, 2007.

4. Pharmaceutical and Chemical Resources for AIDS Drug

Development (PCRADD), Special Emphasis Panel, NIAID, NIH, October 2-3, 2006 and March 8, 2007.

5. New Investigator Program (NIP), American Association of

College of Pharmacy (AACP), 2005.

6. Ad Hoc Reviewers, Small Business Technology Transfer Research (STTR) Program (R41), NIH, June 2000.

D. S-L. Chow

5/9/2012 4

7. Contract Proposals to RFP NIH-NAID-DAIDS-00-11, National

Institute of Allergy and Infectious Diseases, NIH, February, 2000.

8. Small Grants Program (R03), National Institute of Drug Abuse,

NIH, 1997.

9. Earmarked Research Grants, Hong Kong Research Council, 1996 & 1997.

ORGANIZER/MODERATOR OF INTERNATIONAL AND NATIONAL MEETINGS

1. Moderator in Session, Ehrlich II World Conference on Magic Bullets, (for celebrating 100

th Anniversary of Nobel Prize to

Paul Ehrlich, October 3, 2008, Nuremberg, Germany.

2. Organizing Committee, FDA-ANH (Alliance for NanoHealth) Nanotechnology Initiative (FANTI) Workshop, Houston, TX, October 2007- March 2008.

3. Co-Organizer, Co-Chair and Speaker, 2006 ACS-Southwestern

Regional Meeting, Symposium on Biopharmaceutical Considerations in Designs of New Drugs”, Houston, TX, October 18-22, 2006.

4. Moderator in Session “Antineoplastic – New and Known

Synthetic Agents”, Erhlich I World Conference Nurnberg, Germany, September 9-11, 2004.

5. Organizer and Moderator, International Symposium on

Flocculation in Biotechnology & Separation Systems; Session on General and selective flocculation in biological and biomedical applications, San Francisco, CA, July 28 - August 2, 1986.

6. Moderator, Basic Pharmaceutics, American Pharmaceutical

Sciences 37th National Meeting, Philadelphia, PA, October 1984.

PATENTS

1. USA Patent No. 5,430,057* (Granted on July 4, 1995) Parenteral Busulfan for Treatment of Malignant Disease.

D. S-L. Chow

5/9/2012 5

2. USA Patent No. 5,559,148* (Granted on September 24, 1996)

Parenteral Busulfan for Treatment of Malignant Disease - Continuation.

3. Australia Patent No. 694141** (Granted on November 5, 1999)

Parenteral Busulfan for Treatment of Malignant Disease.

4. USA Patent No. 7,419,996 (Granted on September 2, 2008) Parenteral and oral formulations of benzimidazoles

5. International Patent Filing No. PCT/US2004/026168

Pending (Filing date: August 12, 2004). Parenteral and oral formulations of benzimidazoles.

6. USA Patent Filing No. 12/220,374

Pending (Filing date: July 24, 2008) Parenteral and oral formulations of benzimidazoles – Continuation I.


Pending (Filing date: July 24, 2008) Parenteral and oral formulations of benzimidazoles – Continuation II.


Pending (Filing date: June 30, 2010) Parenteral and oral formulations of benzimidazoles – Continuation I-Division of Patent Filing No. 12/220,374.

9. USA Patent Filing No. 13/040,143 Pending (Filing date: March 3, 2011) Diethylstilbestrol dosage form and methods of treatment- Continuation-in-Part of Patent Filing No. 12/608,445 (Filing date: October 29, 2009)

_____________________________ * A commercial product of Busulfex

® based on Patents #1-2 has

been on markets of USA, Canada, Israel, Europe and Asia (46 countries) after FDA approval since February 1999. ** On Australian market since February 2005.

D. S-L. Chow

5/9/2012 6

SCIENTIFIC SOCIETIES

Member, American College of Clinical Pharmacology, 2011-Present Member, New York Academy of Sciences, 2000-Present Member, American Association for Cancer Research, 1995-Present Member, American Association of Pharmaceutical Scientists,

1985-Present Member, Controlled Release Society, 1982-Present Member, Society for In-Vitro Biology (Tissue Culture Association,

1981-1994), 1981-Present Member, American Pharmaceutical Association, 1978-Present

PROFESSIONAL SOCIETIES

Member, American Association of College of Pharmacy, 1982-Present

Member, Pharmacy Examining Board of Canada (P.E.B.C. Registrant of Pharmacists), 1979-Present

RESEARCH ACTIVITIES I. CURRENT RESEARCH ACTIVITIES I-A. Research Interests Significance My research endeavors have been focused on using approaches of pharmaceutical formulations and/or drug delivery systems to enhance or optimize clinical cancer therapies. Recently, the drug delivery efforts have also been expanded to pediatric population and neurologically injured/ disordered patients. By being located at Texas Medical Center, we have been offered ample opportunities for translational research to bring bench-top formulation developments to bed side applications, and vice versa, for clinical therapeutic issue to be addressed in our research. The product of Busulfan

® is one of the most successful examples from our laboratory of such a

translational research that makes significant clinical impacts, benefiting patients receiving blood, marrow or stem cell transplantation. I will continue to offer my expertise and experience in the following areas of research. 1. Translational research on formulation developments of innovative drug delivery systems

for optimal clinical therapies of anti-cancer, anti-AIDS, anti-infectious and neuroprotective agents

Our formulation strategies embrace nano-/microemulsion, nanosuspension, microsphere, liposome and cosolvency. The routes of administration include oral, parenteral and transdermal administrations. The product optimization is pharmacokinetically-guided, with pharmacokinetic/pharmacodynamic (PK/PD) correlation modeling and correlations

D. S-L. Chow

5/9/2012 7

of in-vitro critical formulation parameter characteristics and in vivo PK/PD performance (IVIVC).

The lead product is evaluated for PK/PD in pre-clinical animal models and respective clinical patient populations.

2. Development of formulations for pediatric patients and obese pediatric/adult populations 3. Stability profiles of biotechnological products and small-molecular medications in

clinical settings, and medications in space flights, space station and other space missions. I-B. Major Research Programs in Progress 1. Development of Nanoformulations –

(a) Nano-/microemulsion and nanoparticle formulations of highly insoluble drugs, using CZ48 (lactone-stabilized camptothecin) and other camptothecins, mebendazole, manumycin A, taxol and their derivatives, curcumin and diethylstilbestrol as model compounds for cancer therapies;

(b) Pharmacokinetics-guided formulation optimization, pharmacokinetics and

pharmacodynamic (PK/PD) correlation modeling, and

(c) Formulation parameters of nanomedicine formulations, in vitro characterization of size, surface morphology and zeta potential, and their correlations with in vivo PK/PD performance, to establish in vitro-in vivo correlations (IVIVC).

2. Synergism of combined farnesyltransferase inhibitor with topoisomerase I inhibitor and other

cell-cycle specific chemotherapeutic agents for lung cancer and breast cancer therapies. 3. Developments of sustained formulations of

(a) Neuroprotective/therapeutic agents for glioblastoma model, and

(b) Hydrophilic antibiotics for pulmonary and surgical infectious models 4. Clinical PK/PD investigations of

(a) Neuroprotective agents for acute and chronic spinal cord injury (SCI), as Co-PI of North American Clinical Trial Network (NACTN) on patients of SCI. The NACTN currently comprises nine (9) major hospital centers in USA and Canada, including Methodist Hospital Neuroscience Institute (MHNI), Houston, TX, UT-Memorial Herman Hospital, University of Toronto, University of Virginia Hospital, University of Louisville, University of Maryland, University of Miami and Thomas Jefferson University. UH-COP is the only Pharmacy School participating.

D. S-L. Chow

5/9/2012 8

(b) Anesthesia in obese pediatric patients, collaboration with Texas Children Hospital, and

(c) Transdermal or buccal delivery of synthetic non-steroidal estrogen for recurrent

prostate cancer patients, collaboration with M.D. Anderson Cancer Center. 5. Preclinical Pk/PD investigations, parallel to the above clinical projects in appropriate animal

models II. RESEARCH FUNDING II-A. Royalty Income

From USA Patents No. 5,430,057 and 5,559,148, Busuflex® parenteral formulation for preparative regimen of blood, bone marrow and stem cell transplantations, $9,505,370 to UH, June 1999 – March 2012. The most profitable patent in UH System history The amount reflects 50% of the income after an equal split with M.D. Anderson Cancer Center. The current income is over $1,739,922 annually as an orphan drug, and the patent will continue to the year of 2016.

II-B. Principal Investigator of the Following Sponsored Research Projects:

I have received continuous intra-mural and extra-mural funding other than the royalty incomes since I joined as faculty in COP. The funding level increased significantly in the past twelve (12) years, with a total funding of $986,824 in the past 8 years (June 2003 – June 2011), and $1,388,455 in the past 12.5 years (October 1998 – June 2011). The individual grants are listed as follows:

1. Department of Defense [through Christopher and Dana Reeve Foundation &North

American Clinical Trial Network (NACTN)], ($249,206), June 2008- May 2013. Project: Pharmacokinetics and pharmacodynamic of riluzole in patients with traumatic acute spinal cord injury

2. NASA Johnson Center ($31,500), September 2011- August 2012.

Project: Pharmacokinetics and Pharmacodynamics of intranasal Scopolamine in human subjects during ambulatory and antiorthostatic bed rest conditions

3. NASA Glen Center ($62,705), April – September 2010

Project: Physico-chemical and thermal evaluations of five injectable medications at freeze temperature to 40oC.

4. Progressive Medical Inc. ($30,016), March 2009 - August 2010.

Project: Stability study of vancomycin HCland ceftriazone Na in two elastomeric devices

D. S-L. Chow

5/9/2012 9

(Eclipse Homepump and Accuflow Medpro), Co-PI: Dr. Gupta

5. Tolmar Inc. ($52,441), February 1, 2009 – December 31, 2009. Project: Comparative in vitro evaluation of Tolmar’s liposomal doxorubicin with Doxil.

6. Healix Therapeutics Inc., ($30,836), June 2008 – August 2010.

Project: Stability of imipenem/cilastatin (Primaxin) in three elastomeric devices" Co-PI: Dr. Gupta

7. Pfizer, ($255,000), December 2004-December 2008. Project: Effects of particle size on pharmacokinetic properties of parenteral nano-formulations 7. Gillson Logenbaugh Foundation Award, ($222,500.), June 2003-May 2008. Project: Formulation development for anti-cancer agents (Unrestricted Gift). 8. National Aeronautics and Space Administration; ($129,500), September 2002- December

2007. Project: Pharmacotherapeutics for space in-flight treatments- Stability and new

formulations 9. Advanced Technology Program (ATP), Texas Higher Education Coordinating Board,

($100,000 and $18,909 Supplemental grants for training high school science teachers), January 2002 – August 2004.

Project: Chemoprevention of skin cancers by novel derivatives of tempol in mice and cultures

10. Introgen Therapeutics, ($51,660), July 2001 – June 2002 Project: Development of mebendazole formulations and bioavailability evaluation 11. Wyle Laboratories, ($9,000), July – September 2001 Project: Stability of nitroglycerin in transdermal patches and topical creams recovered

from space flights 12. Sage Pharmaceuticals; ($67,985), June 1996-May 2000 Project: Innovative drug delivery systems for anti-cancer agents 13. SynZyme Technologies; ($24,517), October 1998-August 2000 Project: Pharmacokinetics of SynZyme propriatary derivatives of Tempol using EPR for

drug monitoring 14. ViroTex; ($40,606.2), September 1996 - August 1998 Project: Development of microemulsion formulations for acyclovir and taxol 15. University of Houston (UH), Program to Enhance External Research (PEER), ($5,000),

June 1997-May 1998

D. S-L. Chow

5/9/2012 10

Project: Mechanism of chemoprevention of photodamage and skin cancer by BE-TOPS in Rhino hairless mouse model

16. UH Limited-Grants-In-Aids (LGIA), ($2,000) April - August 1997

Project: Establishment of microdialysis technology for in vivo pharmacokinetic studies in soft tissue of living animals, including tumor and skin

17. UH - LGIA, ($2,000); June - August 1996

Project: Mechanism of photodamage prevention in Rhino mouse skin by mixed diester derivative of tempol.

18. SynZyme Technologies, Inc.; ($9,116), March - December 1996 Project: Suitability of Rhino mouse model for pharmacodynamic evaluation of topical

SynZyme derivatives of Tempol 19. Rhone-Poulenc Rorer; ($44,000), March 1995 - February 1996 Project: Correlation of in vitro and in vivo evaluations of transdermal delivery patches of

estradiol-norethindrone acetate combination (RPR 106522-103A) at various strengths of 50/100, 50/250 and 50/400.

20. UH - LGIA, ($1,700), October 1994 Project: Emergency repair of deep freezer (-80°C) for an ongoing funded project and a

pending clinical phase-1 study. 21. Virotex Corporation; ($9,248), September 1994- April 1995 Project: Formulation development of Dapsone. 22. Orphan Medical Inc.; ($78,732), August 1994 - April 1995

Project: Tissue distributions of busulfan (BU) in Sprague-Dawley rats after single- and multiple-doses of intravenous BU as compared with oral BU administration.

23. UH President's Research Enhancement Fund (PREF), ($4,399), June 1992- May 1993 Project: Transdermal therapeutic systems for treatment of Alzheimer's disease. 24. M.D. Anderson Cancer Center, University of Texas; ($21,203), October 1991 - August

1994 Project: Formulation of intravenous dosage form of busulfan 25. Sage Pharmaceuticals, Inc.; ($19,385.20), September 1991 - August 1994 Project: Antimicrobial activity and clinical bioequivalence evaluation of SSD spray

versus marketed SSD cream product. 26. NIH - Biomedical Research Support Grant (BRSG), ($5,000), April 1991 - March 1992 Project: Sustain release liposomal formulation of Mitomycin C - Pharmacokinetics,

toxicity and anti-tumor efficacy evaluations.

D. S-L. Chow

5/9/2012 11

27. Allergan Pharmaceutical Inc.; ($20,003), February - December 1990 Project: Transdermal permeation, disposition and bioconversion of AGN 190383. 28. UH - LGIA; ($1,200), January 1990 Project: Fabrication of controlled release transdermal therapeutic systems (TTS) of

physostigmine and tetrahydroaminoacridine at Dow Corning Corp., Midland, Michigan. 29. Allergan Pharmaceuticals Inc.; ($14,373), May - December, 1989 Project: Transdermal permeation and disposition of SKF 190168. 30. Greenwich Pharmaceuticals, Inc.; ($25,109), March - November 1989 Project: Transdermal permeation evaluation of Therafectin. 31. FMC Corp.; ($3,466), November 1988 - May 1989 Project: Evaluation of a potential FMC enhancer. 32. The Boots Company (USA), Inc.; ($12,770), June 1988 - December1990 Project: Drug release, transdermal permeation and antimicrobial activity evaluations of

silver sulfadiazine cream. 33. Ortho Pharmaceutical Corp.; ($32,163), June 1988 - May 1989 Project: Skin permeation of tretinoin. 34. NIH - BRSG, ($5,000), April 1988 - March 1989 Project: Structure activity relationship of transdermal permeation enhancers with

molecular level perturbations of stratum corneum. 35. UH - LGIA; ($600), November 1987

Project: Travel grant for attending JUC Pharm Sci 87 Congress, Hawaii, December 1987.

36. UH - LGIA; ($448), April 1987 Project: Travel grant for attending the 29th International Industrial Pharmaceutical

Research Conference Wisconsin, June 1987. 37. NIH - BRSG, ($5,000), April 1987 - March 1988 Project: Transdermal therapeutic systems of physostigmine and tetrahydroaminoacridine

for treatment of Alzheimer's disease. 38. UH - LGIA, ($400), July 1986 Project: Travel grant for attending International Symposium on Flocculation in

Biotechnology and Separation Systems as the Session Organizing Committee member and meeting moderator, California, July 1986.

39. Thera-Tech Inc.; ($17,420), June 1986 - May 1990 Project: Screening of skin permeation barriers.

D. S-L. Chow

5/9/2012 12

40. Conrex Pharmaceutical Corp.; ($37,953), February 1986 – December 1988 Project: Permeation of drugs with Conrex's enhancers, II. 41. Smith Kline & French Laboratories; ($16,858), July - December 1985 Project: In Vitro evaluation of skin permeation of fenoldopam with and without the

influence of penetration enhancers. 42. Conrex Pharmaceutical Corp, ($12,959), June - December 1985 Project: Permeation of drugs with Conrex's enhancers, I. 43. NIH - BRSG, ($5,000), April 1985 - March 1986

Project: Comparative studies on the cutaneous metabolism of xenobiotics in short-term skin organ culture and established skin epithelial and fibroblast cultures.

44. UH - LIGIA; ($500), June-August 1984 Project: Structural elucidation with 300 MHz NMR of the unidentified metabolite

isolated from anthralin-treated hairless mouse skin. 45. Nelson Research and Development Co.; ($10,983) February 1984- August 1985 Project: Cellular uptake of Azone, 1-dodecylazacycloheptan-2-one, by cultured human

skin fibroblasts 46. UH - New Research Opportunities Program (NROP), ($4,500) September 1983 -August

1984 Project: Biochemical characterization of nuclear acceptor binding of glucocorticoid-

dermal receptor complexes in cultured fibroblasts. 47. UH - Research Initiation Grant (RIG); ($1,500), March - August 1982 Project: Effect of Azone, a new accelerant, on percutaneous penetration kinetics of

topical glucocorticoids, and its mechanism. 48. NIH - BRSG, ($2,500), September 1981 - February 1982 Project: The time-dependence of the structural and functional modifications of chromatin

induced by prolonged incubation of topical glucocorticoids in cultured dermal fibroblasts. 49. UH College of Pharmacy, Research Seed Fund, ($5,000), March 1981 Project: Glucocorticoid effects on cultured dermal fibroblasts. II-C. Co-Principal Investigator of the Research Project: 1. Siegfried Ltd.; ($48,290), January 1984 - December 1985 Project: Pharmacokinetic investigations of phenoprobamate in rats and human. Principal Investigator: Dr. C. Lee.

D. S-L. Chow

5/9/2012 13

III. GRADUATE EDUCATION

I have trained two (2) PharmD/Ph.D., twenty-one (21) Ph.D. and seven (7) Masters graduates during 1984 – 2011. They are all well placed in academia (5), Pharmaceutical industry (12), FDA (4), consulting and business. My continuous research funding from pharmaceutical industry has enabled me to train graduate students who were highly sought after even before their graduations. A detailed list of all my graduates and their career placement /advancement is included on p.41-45.

Currently, I am major advisor of eleven (11) Ph.D. students (p. 46). IV. PUBLICATIONS IV-A. Refereed Journal Articles

1. D. S-L. Chow, Y. Teng, E. G. Toups, B. Aarabi, J. Harrop, C.I. Shaffrey, M.M. Johnson, M. Goakye, R.f. Frankowski, M. G. Fehlings, R. G. Grossman, Pharmacology of Riluzole in Acute Spinal Cord Injury, in Focus Issue, Journal of Neurosurgery-Spine, 2012 (in press)

2. A. Gandhi, T. Guo, P. Shah, B. Moorthy, D. Chow, M. Hu and R. Ghose, CYP3A-dependent drug metabolism is reduced in bactierial inflammation in mice. British Journal of Pharmacology, 2012. (in press)

3. J. He, D. A. Figueroa, T-P. Lim, D. S-L. Chow, V. H. Tam, Stability of polymaxin B sulfate diluted in 0.9% sodium chloride injection and stored at 4 or 25oC. Am J Health-Syst Pharm, 67: 1191-1194, 2010.

4. J. He, K.R. Ledesma, W-Y. Lam, D. A. Figueroa, T-P. Lim, D. S-L. Chow, V. H. Tam, Variability of polymaxin B major components in commercial formulations. International Journal of Antimicrobial Agents, 35:305-314, 2010.

5. A. Nornoo, D. Osborne and D. S-L. Chow, Cremophor-free intravenous microemulsions for paclitaxel (I): Formulation, cytotoxicity and hemolysis. International Journal of Pharmaceutics, 10.1016/j.ijpharm.2007.07.042; 349: 108-116, 2008.

6. A. Nornoo and D. S-L. Chow, Cremophor-free intravenous microemulsions for paclitaxel (II): Stability, in vitro release and pharmacokinetics. International Journal of Pharmaceutics, 10.1016/j.ijpharm.2007.07.043; 349: 117-123, 2008.

7. L. Chun, W. Wang, Q. Wu, S. Ke, J. Houston, E. Sevick-Muraca, L. Dong, D. S-L. Chow, C. Charnsangavej and J.G. Gelovani, Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nuclear Medicine and Biology, 33: 349-358, 2006.

D. S-L. Chow

5/9/2012 14

8. I.O. Poon, D. S-L. Chow, and D. Liang, Dissolution profiles of nonprescription

extended-release niacin and inositol niacinate products. American Journal of Health-System Pharmacy (AHSP), 63: 2128 - 2134, 2006.

9. X. Wen, Q-P. Wu, S. Ke, S. Wallace, C. Charnsangavej, P. Huang, D. Liang, D. S-L. Chow and C. Li, Improved radiolabeling of PEGylated protein: Pegylated anexin V for noninvasive imaging of tumor apoptosis. Cancer Biotherapy & Radiopharmaceuticals, 18:819-827, 2003.

10. Y. Zou, Q-P. Wu, W. Tansey, D. S-L. Chow, M.C. Hung, C. Charnsangavej, S. Wallace and C. Li, Effectiveness of water soluble poly(L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice. International Journal of Oncology, 18:331-336, 2001.

11. X. Wen, Q-P. Wu, Y. Lu, Z. Fan, C. Charnsangavej, S. Wallace, D. S-L. Chow and C. Li, Poly(ethylene glycol)-conjugated anti-EGF receptor antibody C225 with radiometal chelator attached to the termini of polymer chains. Bioconjugate Chem. 12:545-553, 2001.

12. B.S. Andersson, T. Madden, H.T. Tran, W.H. Hu, K.G. Blume, D. S-L. Chow, R.E. Champlin and W.P. Vaughan, Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning

therapy; A phase-I study. Biology of Blood and Marrow Transplantation, 6: 548-554, 2000.

13. J. Shah, J.R. Chen and D. Chow, Metastable polymorph of etoposide with higher

dissolution rate, Drug Development and Industrial Pharmacy, 25(1): 63-67, 1999.

14. D. S-L. Chow, H.P. Bhagwatwar, S. Phadungpojna and B.S. Andersson, Stability-indicating high-performance liquid chromatographic assay of busulfan in aqueous and plasma samples. J. Chromatogr. Biomed. Appl., 704: 277-288, 1997.

15. H.P. Bhagwatwar, S. Phadungpojna, D. S-L. Chow and B.S. Andersson, Formulation and stability of busulfan for intravenous administration in high-dose chemotherapy. Cancer Chemotherapy and Pharmacology, 37(5):401-408, 1996.

16. J.C. Shah, J.R. Chen and D. Chow, Preformulation study of Etoposide-II. Increased solubility and dissolution rate by solid-solid dispersions. Int. J. Pharmaceutics, 113:103-111, 1995.

17. D. Liang, D. Chow and C. White, High performance liquid chromatographic assay of cefazolin in rat tissues. J. Chromatogr, Biomed. Appl., 656:460-465, 1994.

18. J.C. Shah, I. Kaka, S. Tenjarla, S.W.J. Lau and D. Chow, Analysis of percutaneous permeation data-II: Evaluation of the lag time method. Int. J. Pharmaceutics, 109:283-

D. S-L. Chow

5/9/2012 15

290, 1994.

19. S.N. Tenjarla and D. S-L Chow, Stability indicating HPLC assay of propranolol for transdermal permeation study. J. Liquid Chromatogr., 16:2899-2913, 1993.

20. J.C. Shah, J.R. Chen and D. Chow, Oral Bioavailability and in-situ absorption of etoposide in rat. Int. J. Pharmaceutics, , 84:223-232, 1992.

21. S.W. J. Lau, D. Chow and S. Feldman, Simultaneous determination of physostigmine and tetrahydroaminoacridine in transdermal permeation study by HPLC. J. Chromatography Biomedical Applications, 526:87-95, 1990.

22. J.C. Shah, J.R. Chen and D. Chow, Preformulation study of etoposide: Possible physicochemical characteristics responsible for low and erratic oral bioavailability of etoposide. Pharmaceutical Research, 6:408-412, 1989.

23. D.S-L Chow and D. Hsieh, Structure activity relationship of permeation enhancers and their possible mechanisms. Pharmaceutical Technology, Fall Conference, Philadelphia, PA, 233-248, 1989.

24. D.S-L. Chow, Book review on Controlled Release of Drugs, M. Rosoff (Ed.), VCH Publisher, 1989; American J. Pharmaceutical Education, 53:323-4, 1989.

25. D.S-L Chow, Book review on Transdermal Controlled Systemic Medications, Y.W. Chien (Ed.), Marcel Dekker, New York, N.Y. 1987; Am. J. Pharmaceutical Education, 52:102 1988.

26. D. Chow, J. Shah and J.R. Chen, Stability-indicating high performance liquid chromatography of etoposide at various pH conditions using reversed-phase octyl column. J. Chromatogr., 356:217-223, 1987.

27. J.X.S. Sun, K. Embil, D.S-L. Chow and C. Lee, HPLC analysis, protein binding and red blood cell partition of phenprobamate. Biopharm. & Drug Disposition, 8:341-351, 1987.

28. S. Bruce, J.A. Tschen and D. Chow, Exogenous Ochronosis resulting from quinine injections. J. Am. Acad. Dermatol., 15:357-361, 1986.

29. D. S-L Chow, I. Kaka and T.I. Wang, Concentration-dependent effect of 1-dodecylaza-cycloheptan-2-one (Azone®), a new enhancer, on the percutaneous penetration kinetics of triamcinolone acetonide. J. Pharm. Sci., 73:1794-1799, 1984.

30. D.S-L. Chow, T.H. Kuo, B. Medeski-Samoraj and C.S. Lee, Disposition of ibuprofen in nephrectomized dogs. J. Pharm. Sci., 73:705-708, 1984.

31. H.O. Senekjian, C.S. Lee, T.H. Kuo, D.S-L. Chow and R. Krothapalli, Absorption and

D. S-L. Chow

5/9/2012 16

disposition of ibuprofen in hemodialyzed uremic patients. European. J. Rheumatology & Inflammation. 6:155-162, 1983.

32. D.S-L. Chow, J.O. Runikis, F.S. Abbott and R. Burton, Gas-Liquid chromatographic analysis of hydrocortisone, triamcinolone acetonide and desonide in culture media of mouse L-929 and human dermal fibroblasts using flame-ionization detection. J. Pharm. Sci., 70: 917-923, 1981.

33. Y.K. Tam, D.S-L Chow and F.S. Abbott, Improved gas-liquid chromatographic flame ionization detection assay of acetylsalicylic and salicylic acids. J. Chromatography, 174: 239-244, 1979.

IV-B. Book Chapter 1. D. S-L. Chow, L. Gong, M.D. Wolfe and B.C. Giovanella, “Modified lactone/carboxylate

salt equilibria in vivo by liposomal delivery of 9-nitrocamptothecin”, The Camptothecins: Unfolding Their Anticancer Potential, Annals of The New York Academy of Sciences, 922: 164-174, 2000.

2. D. Hsieh, D. Chow and J. Chen, “Selective Drug Targeting”, Controlled Released System: Fabrication Technology, Vol. II, CRC Press, pp.145-162 1988. IV-C. Technical Reports 1. Yang Teng and Diana S-L. Chow, Clinical pharmacokinetics and pharmacodynamics of

riluzole in 36 acute spinal cord injured patients of NACTN Phase I Clinical Trial, Report (84 pages) submitted to NACTN (North American Clinical Trial Network for Spinal Cord Injured Patients), October, 2011.

2. Diana S-L. Chow and Ting Zhu, Sustained delivery of hydrophilic Cefazolin using poly (lactic-co-glycolic acid) microspheres - Formulations, pharmacokinetics and in vitro in vivo correlation, Final Report (256 pages) submitted to Pfizer Global Research & Development, Groton, Connecticut, June 22, 2009.

3. Diana S-L. Chow and Yulan Qi, Effects of particle size on pharmacokinetic properties of

nano-formulations. Final Report-Phase II (264 pages) submitted to Pfizer Global Research & Development, Groton, Connecticut, June 22, 2009.

1. Diana S-L. Chow and Tina Zhang, Comparative in vitro evaluations of Tolmar’s

liposomal doxorubicin with Doxil®

, Ortho Biotech Product, Final Report-Phase I (62 pages) submitted to Tolmar Inc. Fort Collins, Colorado, May 25, 2009.

2. Vishnu D. Gupta, Diana S-L. Chow and Fady M. Ibrahim, Stability Study of

Vancomycin HCl (5 and 10 mg/mL) and Ceftriaxone Na (10 and 20 mg/mL) in normal saline in two elastomeric devices (Eclipse Homepump and Accuflow Medpro) at two temperatures, 4 and 25oC, Final Report (31 pages) submitted to Progressive Medical, St.

D. S-L. Chow

5/9/2012 17

Louis , MO. April 3, 2009.

3. Diana S-L. Chow, Vishnu D. Gupta and Fady M. Ibrahim, Stability study of imipenem/cilastatin (Primaxin®) at 2.5 and 5 mg/ml in three elastomeric devices (I-flow HomePumpEclipse, Alaris Readymed and Baxter Intermate) at room and refrigerated (4oC) temperatures, Final Report (69 pages) submitted to Healix Infusion Therapy, Inc., Sugar Land, TX, September 9, 2008.

4. Diana S-L. Chow and Pranav Gupta, Effects of particle size on pharmacokinetic

properties of nano-formulations. Final Report-Phase I (124 pages), Technical Report submitted to Pfizer Global Research & Development, Groton, Connecticut, July 31, 2006.

5. Diana S-L. Chow, Bioanalytical Report for Toxicology Study Protocol WIL 258001

(pages), Technical Report submitted to Orphan Medical, Inc., Minnetonka, Minnesota, March 1, 2003.

6. Diana S-L. Chow and Dong Liang, Development of mebendazole formulations, Interim

Progress Report (34 pages) and Final Report (45 pages) submitted to Introgen Therapeutics, Inc., Houston, TX, January 30, and July 5, 2002, respectively.

7. Diana S-L. Chow and Monica Chuong, Stability of nitroglycerin in transdermal patches

and topical creams recovered from space flights. Technical Reports I (36 pages), II (13 pages), and III (16 pages) and IV (42 pages), submitted to NASA, Houston, TX, August 20, September 14, September 24, 2001 and July 10, 2003, respectively.

8. Diana S-L. Chow and Ling Gong, Preclinical pharmacokinetic study of polynitroxyl

albumin (PNA) in rat model. First Report (53 pages) and Final Report (110 pages), submitted to SynZyme Technologies, Inc., Irvine, CA, January 25 and May 7, 1999, respectively.

9. Diana S-L. Chow and Geneva Chen, Nasal spray formulation of beclomethasone

dipropionate: Optimization and in vitro evaluations. Quarterly Reports to Sage Pharmaceuticals, Shreveport, LA., December 12, 1996, April 1997, July 15, 1997 and June 1998.

10. Diana S-L. Chow and Ling Gong, Suitability of Rhino mouse model for

pharmacodynamic evaluation of topical tempo, and tempo derivatives from SynZyme, First Contract Report (14 pages), March 22, 1996; Pathohistological examination of skin samples from treated mice. Second Contract Report (25 pages), submitted to SynZyme Technologies, Inc., Irvine, CA, December 5, 1996.

11. Diana S-L. Chow and Dong Liang, In vitro evaluations of transdermal delivery patches

of estradiol-norethindrone acetate combination (RPR 106522-103A, later approved product of Combi-Patch) at three strengths of 50/100, 50/250 and 50/400. - Release kinetics and permeation characteristics through human cadaver skin and human fresh skin, (52 pages), Contract Report submitted to Rhone-Poulenc Rorer, Inc., Collegeville,

D. S-L. Chow

5/9/2012 18

PA, March 28, 1996.

12. Diana S-L. Chow and Sasima Phadungpojna, Organ distributions of busulfan (BU) in Sprague-Dawley rats after single- and multiple-doses of intravenous (I.V.) BU as compared with oral BU adminstration, Contract Report 3 (31 pages), submitted to Orphan Medical, Inc., Minnetonka, MN, April 25, 1995.

13. Diana S-L. Chow and Sasima Phadungpojna, Organ distributions of busulfan (BU) in

Sprague-Dawley rats after single-dose of intravenous (I.V.) BU as compared with oral BU adminstration, Contract Report #2 (20 pages) submitted to Orphan Medical, Inc., Minnetonka, MN, March 30, 1995.

14. Diana S-L. Chow, Histological evaluation of organs of Sprague-Dawley rats after single-

and multiple-dose administrations of busulfan (BU) via oral and intravenous routes, Contract Report #1 (9 pages) submitted to Orphan Medical, Inc., Minnetonka, MN, January 20, 1995.

15. Diana S-L. Chow, Clinical evaluation of silver sulfadiazine spray, SPI 9301, versus

Silvadene cream in ten burn patients, Contract Report #6 (8 pages) submitted to Sage Pharmaceuticals, Inc., Shreveport, LA, December 13, 1994.

16. Diana S-L. Chow, Antimicrobial assay of Sage’s Silverspray™ (SSD) against two

strains of micro-organisms, Contract Report #5 (9 pages) submitted to Sage Pharmaceuticals, Inc., Shreveport, LA, January 7, 1994.

17. Diana S-L. Chow, Antimicrobial assay of Sage’s Silverspray™ (SSD) against three

strains of micro-organisms, Contract Report #4 (13 pages) submitted to Sage Pharmaceuticals, Inc., Shreveport, LA, November 10, 1993.

18. Diana S-L. Chow, Evaluation of Sage first aid antiseptics formulations, Clinseptic gel

and Septicare, Contract Report #3 (13 pages) submitted to Sage Pharmaceuticals, Inc., Shreveport, LA, July 26, 1993.

19. Diana S-L. Chow and Harshal Bhagwatwar, Preliminary pharmacokinetic evaluation of

intravenous formulation of busulfan in rats, Contract Report #3 (9 pages) submitted to UT-M.D. Anderson Cancer Center, Houston, TX, November 5, 1992.

20. Diana S-L. Chow, Comparative antimicrobial assay of seven cream/gel formulations of

silver sulfadiazine (SSD), using Micrococcus luteus, Contract Report #2 (11 pages) submitted to Sage Pharmaceuticals, Inc., Shreveport, LA, May 14, 1992.

21. Diana S-L. Chow and Harshal Bhagwatwar, Intravenous formulation of busulfan,

Contract Report #2 (15 pages) submitted to UT-M.D. Anderson Cancer Center, Houston, TX, May 5, 1992.

22. Diana S-L. Chow, Comparative antimicrobial assay of seven cream/gel formulations of

D. S-L. Chow

5/9/2012 19

silver sulfadiazine (SSD), using three strains of micro-organisms, Contract Report #1 (18 pages) submitted to Sage Pharmaceuticals, Inc., Shreveport, LA, February 11, 1992.

23. Diana S-L. Chow and Harshal Bhagwatwar, Feasibility of intravenous formulation of

busulfan, Contract Report #1 (5 pages) submitted to UT- M.D. Anderson Cancer Center, Houston, TX, January 7, 1992.

24. Diana S-L. Chow, Transdermal permeation, disposition and bioconversion of AGN

190383 from a gel formulation using human fresh skin and fuzzy rat skin as barriers, Contract Report #3 (254 pages) submitted to Allergan Pharmaceuticals, Inc., Irvine, CA, November 28, 1990.


190168 from a gel formulation using human fresh skin, human cadaver skin and fuzzy rat skin as barriers, Contract Report #2 (103 pages) submitted to Allergan Pharmaceuticals, Inc., Irvine, CA, November 17, 1989.

26. Diana S-L. Chow, Comparative evaluation of Amiprolose HCl (Therafectin) permeation

from three cream formulations through human cadaver skin, Contract Report #2 (42 pages) submitted to Greenwich Pharmaceuticals, Inc., Fort Washington, PA, November 8, 1989.


190383 from a gel formulation using human fresh skin, human cadaver skin and fuzzy rat skin as barriers, Contract Report #1 (87 pages) submitted to Allergan Pharmaceuticals, Inc., Irvine, CA, October 22, 1989.

28. Diana S-L. Chow, Comparative evaluation of Amiprolose HCl (Therafectin) permeation

from three cream formulations through human cadaver skin, Contract Report #1 (90 pages) submitted to Greenwich Pharmaceuticals, Inc., Fort Washington, PA, September 18, 1989.

29. Diana S-L. Chow, Enhancing effects of five crown ethers on permeation of

triamcinolone acetonide through hairless mouse skin, Contract Report #15 (38 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, May 17, 1989.

30. Diana S-L. Chow, Comparataive evaluation of Tretinoin permeation from Retin-A

cream (#6621-23), reformulated Tretin-A Cream (#6621-43), Tretinoin emollient cream (#6621-45) and PEG 400 ethanolic solution (#6621-47) through human cadaver abdominal skin and fresh facial and breast skin, Contract Report #2 (109 pages) submitted to Ortho Pharmaceutical Corp., Raritan, NJ, March 17, 1989.

31. Diana S-L. Chow, Comparative antimicrobial assay of six cream formulations of sodium

sulfadiazine (SSD) using three strains of micro-organisms, Contract Report #2 (9 pages) submitted to Boots Pharmaceutical Inc., Shreveport, LA, February 20, 1989.

D. S-L. Chow

5/9/2012 20

32. Diana S-L. Chow, Comparative antimicrobial assay of four cream formulations of sodium sulfadiazine (SSD), Contract Report #1 (4 pages) submitted to Boots Pharmaceutical Inc., Shreveport, LA, November 18, 1988.

33. Diana S-L. Chow, Comparative skin permeation of Tretinoin solution (30% propylene

glycol in absolute alcohol) through hairless mouse skin, Rhino hairless mouse skin and human cadaver skin, Contract Report #1 (81 pages) submitted to Ortho Pharmaceutical Corp., Raritan, NJ, August 5, 1988.

34. Diana S-L. Chow, Skin permeation of hydrocortisone in PG-ethanol (1:1) through

hairless mouse skin with and without 2% (v/v) CIB-14, Contract Report #14 (16 pages) submitted to Conrex Pharmaceutical Corp., Brandacore, PA, September 9, 1987.

35. Diana S-L. Chow, Skin permeation of WR-2721 in ethanol through hairless mouse skin

with and without 2% (v/v) CIB-1, Contract Report #13 (14 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, September 9, 1987.

36. Diana S-L. Chow, Skin permeation of indomethacin through human cadaver skin with

and without 2% (v/v) CIB-1, Contract Report #12 (13 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, July 29, 1987.

37. Diana S-L. Chow, Skin permeation of propranolol Hcl through hairless mouse skin in

presence of 10% (v/v) of ethylene brassylate (Astratone) and 5% (w/v) of CIB-9, Contract Report #11 (11 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, December 18, 1986.

38. Diana S-L. Chow, Skin permeation of propranolol base through human cadaver skin in

presence of 5% (w/v) of CIB-1 and 5% (w/v) CIB-9 for 7 days, Contract Report #10 (11 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, October 3, 1986.

39. Diana S-L. Chow, Computer simulation of transdermal drug delivery using transdermal

pharmacokinetic approach (Clonidine, propranolol HCl, prapranolol base, indomethacin and diazepam), Contract Report #9 (53 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, August 22, 1986.

40. Diana S-L. Chow, Skin permeation of hydrocortisone through hairless mouse skin with

2% of CIB-1, CIB-2, CIB-3, CIB-9, CIB-11, CIB-12 or CIB-13, Contract Report #8 (41 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, May 30, 1986.

41. Diana S-L. Chow, Skin permeation of triamcinolone acetonide through hairless mouse

skin with 2% CIB-1 or CIB-10, Contract Report #7 (16 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, March 11, 1986.


skin with 2% CIB-1 or CIB-9, Contract Report #6 (16 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, February 20, 1986.

D. S-L. Chow

5/9/2012 21

43. Diana S-L. Chow, In vitro evaluation of skin permeatin of

14C-fenoldopam

methanesulfonate (SKF 82526-J) with and without the influence of penetration enhancers, Contract Report #2 (190 pages) submitted to Smith Kline & French Laboratories, Philadelphia, PA, January 31, 1986.

44. Diana S-L. Chow, Skin permeation of indomethacin through hairless mouse skin with

and without 2% CIB-1, Contract Report #5 (15 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, December 10, 1985.


skin with various concentrations of CIB-1 and Azone, Contract Report #4 (29 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, November 7, 1985.

46. Diana S-L. Chow, Skin permeation of

14C-fenoldopam methanesulfonate (SKF 82526-J)

through human cadaver abdominal skin with and without 2% (v/v) Azone, Contract Report #1 (24 pages) submitted to Smith Kline & French Laboratories, Philadelphia, PA, October 20, 1985.

47. Diana S-L. Chow, Skin permeation of drugs with and without CIB-1: Summary of

penetration parameters, Contract Report #3 (12 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, October 15, 1985.


skin with 2% of CIB-4, CIB-5, CIB-6, CIB-7 or CIB-8, Contract Report #2 (24 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, September 30, 1985.

49. Diana S-L. Chow, Skin permeation of drugs with and without CIB-1, Contract Report #1

(31 pages) submitted to Conrex Pharmaceutical Corp., Brandamore, PA, August 26, 1985.

V. PRESENTATIONS V-A. Invited Seminars and Lectures: 1. North American Clinical Trial Network (NACTN) Meeting, Toronto, Ontario, Canada,

March 18, 2011. “Pharmacokinetics and pharmacodynamics of riluzole in patients with acute traumatic spinal cord injury”.

2. University of Toronto, Leslie Dan Faculty of Pharmacy, March 16, 2011. “Nanoformulations for Cancer Therapy with Significant Impacts on Pharmacokinetics and

Pharmacodynamics”.

D. S-L. Chow

5/9/2012 22

3. The 6th

Annual Congress of International Drug Discovery Science and Technology (IDDST), Beijing, China”,October 18-22, 2008.

“Approaches of Nanomedicine Formulations in Cancer Therapy for Achieving Significant Impacts on Pharmacokinetics and Biodistributions” (Invited Lecturer).

4. Ehrlich II World Conference on Magic Bullets, (for celebrating 100

th Anniversary of Nobel

Prize to Paul Ehrlich), Nuremberg, Germany, October 3-5, 2008. “Nanomedicine – self-nanoemulsifying drug delivery system (SNEDDS) and nanosuspension for oral and parenteral formulations in cancer therapy with significant impacts on pharmacokinetics and biodistributions” (Invited Lecturer).

5. 2008 Canadian Society of Pharmaceutical Sciences (CSPS) Symposium, Banff, Alberta, Canada, May 22-25, 2008. “Approaches of self nanoemulsifying drug delivery system (SNEDDS) and nanosuspension for oral and parenteral formulations in cancer therapy with significant impacts onpharmacokinetics and biodistributions” [Did not make the presentation due to family emergency.]

6. North American Clinical Trial Network (NACTN) Meeting, Texas Medical Center, Houston,

TX, February 18, 2008. “Pharmacokinetics of riluzole in patients with traumatic spinal cord injury”.

7. 2006 ACS-Southwestern Regional Meeting, Symposium on Biopharmaceutical Considerations

in Designs of New Drugs”, Houston, TX, October 9-22, 2006. “Pharmacokinetic considerations in drug discovery and development”.

8. Silver Anniversary Celebration, College of Pharmacy, University of Houston, at Texas

Medical Center, November 11, 2005. “Novel drug delivery strategies for optimization of cancer therapy- Collaborations with scientists and clinicians at Texas Medical Center”.

9. Texas Southern University, College of Pharmacy and Health Sciences, Houston, TX, October 13, 2004. “Potentials of innovative delivery of lactone-stabilized camptothecin, CZ48”.

10. University of Houston, Department of Pharmacological and Pharmaceutical Sciences,

Houston, TX, October 12, 2004. “Potentials of innovative delivery of lactone-stabilized camptothecin, CZ48”.

11. Ehrlich I World Conference on Dosing Antiinfectives and Symposium on New Anti-

neoplastic Agents, Nuremberg, Germany, September 9-11, 2004. “ Enhanced antineoplastic efficacy in vivo of lactone-stabilized camptothecins by chemical modification or liposomal delivery (Invited Lecturer).


Houston, TX, October 16, 2000.

D. S-L. Chow

5/9/2012 23

“Camptothecins: unfolding their anticancer potential”. 13. Conference on The Camptothecins: Unfolding Their Anticancer Potential”,

Ritz-Carlton Pentagon City, Arlington, Virginia, March 17-20, 2000. “Modified lactone/carboxylate salt equilibria in vivo by liposomal delivery of 9-nitrocamptothecin” (Plenary Lecturer).


Houston, TX, April 7, 1994. “Drug Delivery Systems”.

15. University of Houston, Pharmacology Graduate Program, Houston, TX, October 26,

1993. “Development of Transdermal Therapeutic Systems for Alzheimer’s Disease”.

16. University of Texas at Houston, School of Public Health, Houston, TX, September 23, 1993. “Pharmaceutical Applications of New Gene Technology”.

17. TV Channel 22, Science and Culture Program, Houston, TX, August 26, 1992.

“Transdermal Controlled Released Medications”. 18. Dow Corning Corp., Midland, MI, January 16, 1990.

“Transdermal delivery of propranolol: preformulation and prototype fabrication study”.

19. Pharm. Tech. Fall Conference 89, Philadelphia, PA, September 20, 1989. “Structure activity relationship of permeation enhancers and their possible mechanisms”.

20. Greenwich Pharmaceuticals, Inc., Fort Washington, PA, June 26, 1989.

“Transdermal permeation of therafectin (amiprilose HCl) from gel and cream formulations through human cadaver skin”.

21. University of Maryland, Department of Pharmaceutics, School of Pharmacy,

Baltimore, MD, February 6, 1989. “Comparative enhancer effects on drug permeation through human skin and hairless mouse skin”.

22. Ortho Pharmaceutical Corp., Raritan, NJ, April 11, 1988.

“Comparative permeation of drugs through human cadaver skin and hairless mouse skin”.

23. University of Houston, Department of Pharmacology, Houston, TX, March 20, 1988. “Differential enhancer effect on drug permeation through human skin and hairless mouse skin”.

D. S-L. Chow

5/9/2012 24

24. Boots Pharmaceutical Inc. (USA), Shreveport, LA, January 26, 1988.

“Feasibility of L-thyroxin and triiodothyronine for transdermal therapeutic systems”. 25. Boots Pharmaceutical Inc. (USA), Shreveport, LA, January 26, 1988.

“Drug release, transdermal permeation and antimicrobial activity evaluations of silver sulfadiazine cream”.

26. Texas Anticancer Drug Development Consortium, San Antonio, TX, November 7,

1986. “Transdermal drug delivery systems”.

27. Association of Chinese Biomedical Professionals, Annual Meeting, Houston, TX,

November 16, 1985. “Treatment and prevention of AIDS”.

28. University of Houston, Continuing Education Program, College of Pharmacy,

Houston, TX, March 19 - April 17, 1985. “New dosage forms and drug delivery systems”.

29. University of British Columbia, Faculty of Pharmaceutical Sciences, B.C. Canada,

August 17, 1984. “Concentration-dependent kinetics of Azone-enhanced percutaneous penetration of triamcinolone acetonide”.

30. University of British Columbia, Department of Dermatology, Faculty of Medicine,

B.C. Canada, August 16, 1984. “Enhancing effects of Azone on percutaneous penetration of triamcinolone acetonide and their possible mechanisms”.

31. Association of American-Chinese Professionals, Annual Meeting, Science, Engineering and Technology Seminars, May 27, 1984. “Controlled release medications”.

32. Letterman Army Institute of Research, Division of Cutaneous Hazards,

Presidio of San Francisco, CA, July 29, 1983. “Nuclear retention of triamcinolone acetonide and absence of cross-linking with DNA in cultured dermal fibroblasts”.

V-B. National and International Meetings and Conferences:

1. Y. Teng, E. Toups, R. Grossman, Diana S-L. Chow, “Effects of Different Formulations on Riluzole Pharmacokinetics”. Presented in 25th Annual Meeting, American Association of Pharmaceutical Scientists (AAPS), Washington, DC, October 23-27, 2011.

D. S-L. Chow

5/9/2012 25

2. Dong Dong, Beppino C. Giovanella, and Diana S-L. Chow, “Nanosuspensions of CZ48, Lactone-Stabilized Prodrug of Camptothecin- Pharmacokinetics and Organ Distribution of Intravenous Administration in Rats”. Presented in 25th Annual Meeting of AAPS, Washington, DC, October 23-27, 2011.

3. Tanay Samant1, Shi-Ming Tu2 and Diana S-L. Chow, “Pharmacokinetics and

Pharmacodynamics of Diethylstilbestrol Nanosuspension in Rats”. Presented in 25th Annual Meeting of AAPS, Washington, DC, October 23-27, 2011.

4. Lei Wu, V. R. Daniels, C. J. Crady, Diana S-L. Chow and Lakshmi Putcha,

“Pharmacokinetics of intranasal scopolamine gel formulation during antiorthostatic bedrest - a microgravity analog”. Presented in 25th Annual Meeting of AAPS, Washington, DC, October 23-27, 2011.

5. Cheng-Hui Hsiao, Olutoyin A. Olutoye, Dong Liang, and Diana S-L. Chow,

“Pharmacokinetics and Pharmacodynamics of Propofol in Pediatric Obese Population”. Presented in 25th Annual Meeting of AAPS, Washington, DC, October 23-27, 2011.

6. Jui-Chen Tsai, Dong Dong, Hsin-Yi Lai, and Diana S-L. Chow, “Development of Curcumin

Nano/microemulsions for Versatile Routes of Administration”. Presented in 25th Annual Meeting of AAPS, Washington, DC, October 23-27, 2011.

7. Jie He, V.H. Tam and Diana S-L. Chow, “Plasma Protein Binding of Polymyxin B Major

Components in Three Mammalian Species”. Presented in 25th Annual Meeting of AAPS, Washington, DC, October 23-27, 2011.

8. Zheng Wang, Olson Chu, Roland Ako and Diana S-L. Chow, “Preparation and

Characterization of NAL1892 Diethylstilbestrol Orally Dissolving Film (ODF)”. Presented in 25th Annual Meeting of AAPS, Washington, DC, October 23-27, 2011.

9. Roland Ako, Shi-Ming Tu and Diana S-L. Chow, “Effect of Diethylstilbestrol on Levels of Prostate Specific Antigen and Clotting Factor in Patients with Recurrent Prostate Cancer”. Presented in the 40

thAnnual Meeting of American College of Clinical Pharmacology (ACCP),

Chicago, IL, September 11-13, 2011. [Winner of ACCP President’s Student Abstract Award]

10. Diana S-L. Chow, Yang Teng, Elizabeth G. Toups, Bizhan Aarabi, James S. Harrop, Christopher I. Shaffrey, Michele M. Johnson, Maxwell Boakye, Michael G. Fehlings and Robert G. Grossman, “ Clinical Pharmacokinetics of Riluzole in Acute Spinal Cord Injured Patients”. Presented in the 40

thAnnual Meeting of ACCP, Chicago, IL, September 11-13,

2011. 11. Dong Dong, Beppino C. Giovanella, and Diana S-L Chow, “Optimization and

pharmacokinetics of nanoformulation of CZ48, lactone-stabilized prodrug of camptothecin”. Presented in the 38

thAnnual Meeting and Exposition of the Controlled Release Society (CRS),

Washington, DC, July 30-August 3, 2011.

D. S-L. Chow

5/9/2012 26

12. Tanay Samant and Diana S-L Chow, “Formulation, in vitro release and pharmacokinetics of

diethylstilbestrol nanosuspension in rats”. Presented in the 38th

Annual Meeting and Exposition of the CRS, Washington, DC, July 30-August 3, 2011.

13. Tanay Samant and Diana S-L. Chow, “Development of nanosuspension formulation of

diethylstilbestrol and effect of particle size on the in vitro drug release”. Presented in the 102nd Annual Meeting of American Association for Cancer Research (AACR), Orlando, FL, April 3, 2011.

14. Roland Ako, Shi-Ming Tu and Diana S-L. Chow, “Comparative pharmacokinetics of

diethylstilbestrol from oral suspension and oral dissolving film (ODF)”. Presented in the 102nd Annual Meeting of AACR, Orlando, FL, April 4, 2011.

15. Fady Ibrahim, Kemi Cui, Pamela New, Lulu Wang, Hong Zhao, Stephen Wong and Diana S-L. Chow, “Dual Efficacy of Lazaroid U-74389G Liposomes in Glioblastoma Mouse Model”. Presented in the 102nd Annual Meeting of AACR, Orlando, FL, April 6, 2011.

16. Dong Dong, Beppino C. Giovanella, and Diana S-L. Chow, “Nanosuspension of CZ48,

lactone-stabilized prodrug of camptothecin-formulation development and characterization”. Presented in 24th Annual Meeting of AAPS, New Orleans, Louisiana, November 14-18, 2010.

17. Yang Teng, Yongchao Wu, Michael G. Fehlings, Robert G. Grossman and Diana S-L.

Chow, “Pharmacokinetics of riluzole in plasma, brain and different segments of spinal cord in rat model”, Presented in 24th Annual Meeting, AAPS, New Orleans, Louisiana, November 14-18, 2010.

18. Tanay Smanat, Chinonyerem Igboagi, Fady Ibrahim and Diana S-L. Chow, “Liquid

chromatography tandem mass spectrometric (LC-MS/MS) assay for dexmedetomidine in human plasma samples”. Presented in 24th Annual Meeting, AAPS, New Orleans, Louisiana, November 14-18, 2010.

19. Fady Ibrahim, Pamela New and Diana S-L. Chow, “Pharmacokinetics and biodistribution

of Lazaroid U74389G liposomes in mice”. Presented in 24th Annual Meeting, AAPS, New Orleans, Louisiana, November 14-18, 2010.

20. J. He, V.H. Tam and D. S-L. Chow, “Effects of nanoemulsion on pharmacokinetic and

biodistribution of polymyxin B”. Presented in 24th Annual Meeting, AAPS, New Orleans, Louisiana, November 14-18, 2010.

21. Cheng-Hui Hsiao, Dong Liang and Diana S-L. Chow, “Pharmacokinetics and

pharmacodynamics of propofol in obese and lean rats”. Presented in 24th Annual Meeting, AAPS, New Orleans, Louisiana, November 14-18, 2010.

D. S-L. Chow

5/9/2012 27

22. Roland Ako, Shi-Ming Tu and Diana S-L. Chow, “Transdermal delivery of diethylstilbestrol in preclinical mouse model”. Presented in 24th Annual Meeting, AAPS, New Orleans, Louisiana, November 14-18, 2010.

23. Fady Ibrahim, Pamela New and Diana S-L. Chow. “Passive Lung Targeting of Lazaroid

U-74389G with Nanosuspension and Liposomal Formulations”, Presented in the 37

thAnnual Meeting and Exposition of the CRS, Portland, OR, July 10-14, 2010.

24. Fady Ibrahim, Pamela New and Diana S-L. Chow. “Formulation and pharmacokinetics of

Lazaroid U-74389G (LAZ) liposomes in rats”. Presented in the 101stAnnual Meeting of

AACR, Washington, DC, April 17-21, 2010.

25. Fady Ibrahim, Pamela New and Diana S-L. Chow. “Effects of particle size and charge modification on biodistribution of Lazaroid U74389G from nanosuspensions”. Presented in 23rd Annual Meeting of AAPS, Los Angeles, CA, November 8-12, 2009.

26. Ting Zhu, Jinyang Hong, Jaymin C. Shah and Diana S-L. Chow. “Development and

validation of in vitro-in vivo correlation (IVIVC) for sustained-release Cefazolin-loaded PLGA microspheres”. Presented in 23rd Annual Meeting, AAPS, Los Angeles, CA, November 8-12, 2009.

27. Roland Ako, Fady Ibrahim, Johnny S.W. Lau, Patricia Jensen-Loewe, Shi-Ming Tu and Diana S-

L. Chow. Liquid chromatography tadem mass spectrometry (LC/MS/MS) assay for diethylstilbestrol in plasma samples of recurrent prostate cancer patients”. Presented in 23rd Annual Meeting, AAPS, Los Angeles, CA, November 8-12, 2009.

28. Yang Teng, Elizabeth G. Toups, Robert G. Grossman and Diana S-L. Chow. “High

performance liquid chromatographic assay for Riluzole in human plasma and cerebrospinal fluid (CSF) samples”. Presented in 23rd Annual Meeting, AAPS, Los Angeles, CA, November 8-12, 2009.

29. Jie He, D.A. Figueroa, Diana S-L. Chow, Vincent H. Tam. “Stability of polymyxin B

(PB) sulfate in saline infusion bags at different storage temperatures”. Presented in 23rd Annual Meeting, AAPS, Los Angeles, CA, November 8-12, 2009.

30. Fady Ibrahim, Pamela New, Bin S. Teh and Diana S-L. Chow. “Comparative release

profiles of Lazaroid U-74389G microspheres in plasma and CSF”. Presented in the 100

thAnnual Meeting of AACR, Denver, CO, April 18-22, 2009.

31. Diana S-L. Chow, Roland Ako, Fady Ibrahim, Johnny S.W. Lau, Patricia Jensen-Loewe

and Shi-Ming Tu. “Pharmacokinetics and efficacy of oral diethylstilbestrol (DES) in recurrent prostate cancer”. Presented in the 100

thAnnual Meeting of AACR, Denver, CO,

April 18-22, 2009.

D. S-L. Chow

5/9/2012 28

32. Elimika Pfuma, Beppino Giovanella, Jim Sai-Ching Yeung and Diana S-L. Chow. “Combination efficacy of CZ48 and manumycin A in NSCLC H460 bearing Swiss athymic mouse model”. Presented in the 100

thAnnual Meeting of AACR, Denver, CO,

April 18-22, 2009.

33. Ting Zhu, Jinyang Hong, Jaymin C. Shah and Diana S-L. Chow. “Differential pharmacokinetic performance of cefazolin loaded poly (D,L-lactide-co-glycolide) microspheres of various release kinetics in rat model and their in vitro-in vivo correlations”. Presented in the 22nd Annual Meeting, AAPS, Atlanta, GA, November 11-15, 2008.

34. Elimika Pfuma, Beppino Giovanella, Jim Sai-Ching Yeung and Diana S-L. Chow.

“Pharmacokinetic dose linearity and tumor/plasma exposures of CZ48 in Swiss athymic mouse model”. Presented in the 22nd

Annual Meeting, AAPS, Atlanta, GA, November 11-15, 2008.

35. Ting Zhu, Jinyang Hong, Jaymin C. Shah and Diana S-L. Chow. “Distinct pharmacokinetic performance of biodegradable microspheres of hydrophilic cefazolin with different release characteristics”. Presented in the 35

thAnnual Meeting and Exposition

of the Controlled Release Society (CRS), New York, NY, July 12-16, 2008.

36. Yulan Qi, Pranav Gupta, Diana S-L. Chow. “Comparative inter-species scaling and prediction of human pharmacokinetic parameters of antineoplastic mebendazole from nanoemulsions of different droplet sizes”, Presented in the 99

thAnnual Meeting of AACR,,

San Diego, CA., April 12-16, 2008.

37. Diana S-L. Chow , Pranav Gupta, Peter Wisniecki and Jaymin C. Shah . “Significant

impact of drug nanoparticle size on pharmacokinetic disposition of IV antineoplastic mebendazole in rat model”. Presented in the 21

st Annual Meeting, AAPS, San Diego, CA,

November 11-15, 2007.

38. Ting Zhu, Jinyang Hong, Jaymin C. Shah and Diana S-L. Chow. “Biodegradable microspheres of hydrophilic cefazolin for sustained release formulations”. Presented in the 21

st Annual Meeting, AAPS, San Diego, CA, November 11-15, 2007.

39. Yulan Qi, Peter Wisniecki, Jaymin C. Shah and Diana S-L. Chow . “Comparative

pharmacokinetics and biodistribution of antineoplastic mebendazole from cosolvent and nanosuspension formulations in Swiss nude athymic mice”. Presented in the 21

st Annual

Meeting, AAPS, San Diego, CA, November 11-15, 2007.

40. Elimika Pfuma, Beppino Giovanella, Jim Sai-Ching Yeung and Diana S-L. Chow. “Pharmacokinetics of combination treatment of CZ48 with manumycin A in Swiss athymic mouse model”, Presented in the 21

st Annual Meeting, AAPS, San Diego, CA,

November 11-15, 2007.

D. S-L. Chow

5/9/2012 29

41. Yousif Rojeab, Beppino C. Giovanella and Diana S-L. Chow. “In vitro and in vivo

evaluations of microemulsion formulations of CZ48, lactone-stabilized camptothecin-C

20propionate, for transdermal delivery”. Presented in the 34

th Annual Meeting and

Exposition of the CRS, Long Beach, CA, July 7-11, 2007.

42. Yulan Qi, Pranav Gupta and Diana S-L. Chow, Comparative pharmacokinetics and biodistributions of mebendazole from cosolvent and nanoemulsion formulations in nude athymic mice. Presented in the 98

th Annual Meeting of AACR, Los Angeles, CA., April 16,

2007.

43. Yousif Rojeab, Beppino C. Giovanella and Diana S-L. Chow. “Comparative pharmacokinetics of microemulsion of CZ48, lactone-stabilized camptothecin-C20-propionate, from different routes of administration in nude mice”. Presentation in the 98

th

Annual Meeting of AACR, Los Angeles, CA., April 16, 2007.

44. Ting Zhu, Rania Haddadin, Dong Liang and D S-L. Chow, Biodegradable microsphere formulations for CZ48, a lactone-stabilized camptothecin, for potential combination cancer therapy. Presented in the 20

thAnnual Meeting, AAPS, San Antonio, Texas,

November 2, 2006.

45. Y. Rojeab, B. Giovanella and D S-L. Chow, Topical application of microemulsion of CZ48, lactone-stabilized camptothecin-C20 propionate, in Swiss-nude mice. Presented in the 20

th Annual Meeting, AAPS, San Antonio, Texas, October 30, 2006.

46. P. Gupta, D. Liang, J. Ma and D.S-L.Chow, Self-emulsifying (SEDDS) and self-

microemulsifying drug delivery systems (SMEDDS) for improved oral bioavailability of mebendazole: Effects of particle size and lipid digestion. Presented in the 33

rd Annual

Meeting and Exposition of the CRS, Vienna, Austria, July 22-26, 2006.

47. D.S-L.Chow, D.N. Wang, T. Nguyen, D.G. Hwang, B. Stanley, B. Giovanella, S-C. J. Yeung, Scheduling as a factor in combination therapy of a farnesyltransferase inhibitor, manumycin A, with other cell cycle specific chemotherapeutic agents for lung cancer. Presented in the 97

th Annual Meeting of AACR, Washington D.C., April 3, 2006.

48. R. Dababneh, D.S-L.Chow, S-C. J. Yeung, Sequential versus concurrent treatment of

breast cancer cell lines using the farnesyl treansfease inhibitor, manumycin A, and mebendazole. Presented in the 97

th Annual Meeting of AACR, Washington D.C., April 3,

2006.

49. Yousif Rojeab, Beppino C. Giovanella and Diana S-L. Chow, Microemulsion-based gel (MBG) formulations of CZ48, lactone-stabilized camptothecin-C20-propionate, for transdermal delivery. Presented in the 19th Annual Meeting, AAPS, Nashville, Tennessee,

D. S-L. Chow

5/9/2012 30

November 10, 2005.

50. Pranav Gupta, Jing Ma, Dong.Liang, D. S-L. Chow, Comparative bioavailability studies of oral self-nanoemulsifying formulation versus intravenous co-solvent and microemulsion formulations of antineoplastic mebendazole. Presented in the 19th Annual Meeting, AAPS, Nashville, Tennessee, November 9, 2005.

51. P.Gupta, D.Liang, J.Ma and D.S-L.Chow, Self-microemulsifying drug delivery

system (SMEDDS) for improved oral bioavailability of mebendazole. Presented in the 32

ndAnnual Meeting and Exposition of the CRS, June 21-22, 2005.

52. D. S-L. Chow, D. Liang, L. Cho and S-C J. Yeung, Enhanced cytotoxicity of CZ48,

lactone-stabilized camptothecin-C20-propionate, by farnesyltransferase inhibitor in lung cancer cultures. Presented in the 96

th Annual Meeting of AACR, Anaheim,

California, April 19, 2005.

53. Yousif Rojeab, Beppino C. Giovanella and Diana S-L. Chow, Evaluation of transdermal permeation and plasma protein binding of CZ48, lactone-stabilized camptothecin-C20-propionate, in vitro using microdialysis technique. Presented in the 96

th Annual Meeting of AACR, Anaheim, California, April 17, 2005.

54. Pranav Gupta, Dong.Liang, D. S-L. Chow, Oral microemulsion formulation for

mebendazole, a novel- anticancer agent. Presented in the 18th National Meeting, AAPS, Baltimore, Maryland, November 10, 2004.

55. Rania Haddadi, Dong Liang and Diana S-L. Chow, High performance liquid

chromatographic assay for simultaneous quantifications of manumycin A and camptothecins in perfusates of microdialysis. Presented in the 18th National Meeting,

AAPS, Baltimore, Maryland, November 9, 2004. 56. Diana S-L. Chow, Yousif Rojeab, Beppino C. Giovanella, Stable prototype microemulsion formulation of CZ48, lactone-stabilized camptothecin-C

20-propionate.

Presented in the 18th National Meeting, AAPS, Baltimore, Maryland, November 9, 2004.

57. M. Chuong, L. Putcha and D. S-L. Chow, Comparison of detection sensitivity

between vertical Franz diffusion cell and enhancer cell in evaluations of in vitro drug release changes of two thermally or irradiated-degraded topical glucocorticoid creams. Presented in the 18th National Meeting, AAPS, Baltimore, Maryland, November 8,

2004 58. D. S-L. Chow, M. Chuong, T. Baysue and L. Putcha, Pharmaceutical stability of NitroDur patch and two topical creams flown on space missions. Presented in the 75

th

Aerospace Medical Association Annual Scientific Meeting: Frontiers in Aerospace Medicine, Anchorage, Alaska, May 6, 2004.

D. S-L. Chow

5/9/2012 31

59. D. S-L. Chow, Y. Rojeab, B.G. Giovanella, Microemulsion formulations of CZ48, lactone-stabilized camptothecin-C20-propionate, for transdermal delivery. Presented

in the 95th

Annual Meeting of AACR, Orlando, Florida, March 31, 2004. 60. D. S-L. Chow, D. Liang, Leah Cho, E.Wang and S-C J. Yeung, Synergistic

cytotoxicity of combinations of farnesyltransferase inhibitor and topoisomerase I inhibitor in non-small cell lung cancer cultures. Presented in the 95

th Annual Meeting

of AACR, Orlando, Florida, March 29, 2004. 61. D. S-L. Chow, W. Jiang, B. Stanley, H.N. Ananthaswamy, Chemoprevention of novel

derivatives of tempol against UV-B induced cellular damages and skin cancer development in hairless mice. Presented in the 95

th Annual Meeting of AACR, Orlando,

Florida, March 28, 2004. 62. X Li, B.C. Giovanella and D. S-L. Chow, Dose linearity of CZ48, lactone-stabilized

camptothecin-C20-propionate, after intravenous administration in rats. Presented in the 17th National Meeting, AAPS, Salt Lake City, Utah, October 29, 2003.

63. D. S-L. Chow, D. Liang, P. Gupta, H. Yang, A. Stewart, A. Mhashikar, J.A. Roth, T.

Mukhopadhyay and S. Chada, Parenteral and oral formulations of a novel microtubule inhibitor for antineoplastic indications, Presented in the 17th National Meeting, AAPS, Salt Lake City, Utah, October 28, 2003.

64. M. Chuong and D. S-L. Chow, Comparison of vertical Franz diffusion cell system and

USP dissolution apparatus with enhancer cells in evaluations of in vitro drug release characteristics of two topical glucocorticoid formulations. Presented in the 17th National Meeting, AAPS, Salt Lake City, Utah, October 28, 2003.

65. D. S-L. Chow, X Li, D. Liang, and B.C. Giovanella, Comparative preclinical

pharmacokinetics of CZ48, lactone-stabilized camptothecin- C20

-propionate with

intravenous and oral administrations in rats. Presented in the 94th

Annual Meeting of AACR Washington D.C., July 13, 2003.

66. D. S-L. Chow, W. Jiang, B. Stanley, H.N. Ananthaswamy, Chemoprevention of novel

derivatives of tempol against UV-B induced apoptosis in cultured human melanoma cells. Presented in the 94

th Annual Meeting of AACR, Washington D.C., July 12, 2003.

67. D. Liang, R. Chaudhary, Y. Rojeab, S. Chada and D. S-L. Chow, Preformulation evaluation of anthelmintic imidazole for anti-neoplastic indications. Presented in the 16th National Meeting, AAPS, Toronto, Ontario, Canada, November 12, 2002. 68. X Li, D. Liang, B.C. Giovanella and D. S-L. Chow, Comparative pharmaco-

kinetics of CZ48, lactone-stabilized camptothecin-C20

-propionate and camptothecin.

D. S-L. Chow

5/9/2012 32

Presented in the 16th National Meeting, AAPS, Toronto, Ontario, Canada, November 13, 2002.

69. M. Chuong, L. Putcha, T.M. Bayuse, and D. S-L. Chow, Evaluation of pharmaceutical

stability of nitroglycerin (NitroDur) patch and desoximetasone (Topicort) cream during space flights. Presented in the 16th National Meeting, AAPS, Toronto, Ontario, Canada, November 13, 2002.

70. Xiaoxia Wen, Qing-ping Wu, Peng Huang, Diana S-L. Chow, Sidney Wallace,

Chusilp Charsangavej, Chun Li, Imaging of apoptosis with 111

In labeled pegylated annexin V, AACR-NCI Symposium on Molecular Imaging in Cancer, Orlanda, Florida,

January 23-27, 2002. 71. J. Ling, J. Wosik, L. Ma, Y.J. Wang, C. Hsia and D. S-L. Chow, Stability kinetics of polynitroxyl albumin (PNA) in ascorbate solution and rat tissue homogenates, Presented in the 15th National Meeting, AAPS, Denver, Colorado, October 22, 2001. 72. D. S-L. Chow, Xiaohui Li and B.C. Giovanella, Potential of transdermal delivery of anti-cancer agents, camptothecin (CPT) and CZ48, 20-propyl-CPT. Presented in the 15th National Meeting, AAPS, Denver, Colorado, October 22, 2001. 73. D. S-L. Chow, J. Ling, L. Gong, J. Wosik, L. Ma, Y.J. Wang, and C. Hsia, Polynitroxyl albumin (PNA): a sustained delivery system of free radical scavenger, tempol. Presented in the 28th International Symposium on Controlled Release of Bioactive Materials, San Diego, California, June 27, 2001. 74. D. S-L. Chow, Xiaohui Li and B.C. Giovanella, Feasibility of transdermal delivery camptothecin (CPT) and CZ48, 20-propyl-CPT derivative. Presented in the 92nd Annual Meeting of AACR, New Orleans, LA, March 2001. 75. J. Ling, L. Gong, J. Wosik, L. Ma, Y.J. Wang, C. Hsia and D. S-L. Chow, Organ

distribution of polynitroxyl albumin (PNA) in rats using electron spin resonance (ESR) for drug monitoring, Presented in the 14th National Meeting, AAPS, Indianapolis, Indiana, November 1, 2000.

76. M.D. Wolfe, L. Gong, B.C. Giovanella and D. S-L. Chow, Anti-tumor efficacy and

drug in tumor after intramuscular (IM) delivery of liposomal 9-nitro-camptothecin (lipo-9NC) in athymic mice. Presented in the 14th National Meeting, AAPS, Indianapolis, Indiana, October 31, 2000.

77. D. S-L. Chow, M.D. Wolfe and B.C. Giovanella, Intramuscular (I.M.) delivery of

liposomal 9-nitro-camptothecin (9NC) in tumor bearing athymic mouse model. Presented in the 91st Annual Meeting of AACR, San Francisco, California, April 2000.

78. D. S-L. Chow, L. Gong, J. Ling, L. Ma, Y.J. Wang and C. Hsia, Preclinical

pharmacokinetics of polynitroxyl albumin (PNA) in rats. Presented in the 13th

D. S-L. Chow

5/9/2012 33

National Meeting, AAPS, New Orleans, Louisiana, November 1999. 79. D. S-L. Chow, L. Gong, J. Ling, J. Wosik, L. Ma, Y.J. Wang and C. Hsia, Electron

paramagnetic resonance (EPR) assay of polynitroxyl albumin (PNA) for pharmacokinetic and biodistribution evaluations. Presented in the 13th National Meeting, AAPS, New Orleans, Louisiana, November 1999.

80. A.O. Nornoo, D.W. Osborne, J.R. Chen and D. S-L. Chow, Parenteral microemulsion of paclitaxel: Formulation, pharmacokinetics and cytotoxicity in cancer cell line, Presented in the 26th International Symposium on Controlled Release of Bioactive Materials, Boston, Massachusetts, June 1999. 81. L. Gong, B.C. Giovanella and D. S-L. Chow, Sustained organ exposure to 9-nitro- camptothecin (9NC) lactone form by liposomal delivery. Presented in the 90th Annual Meeting of AACR, Philadelphia, Pennsylvania, April 1999. 82. A.O. Nornoo, D.W. Osborne, J.R. Chen and D. S-L. Chow, Development and

Pharmacokinetics of an intravenous microemulsion of paclitaxol. Presented in the 12th National Meeting, AAPS, San Francisco, California, November 1998.

83. L. Gong and D. S-L. Chow, Pharmacoikinetics and biodistribution of liposomal 9 -nitro-camptothecin (9NC) and free 9NC in rats. Presented in the 12th National Meeting, AAPS, San Francisco, California, November 1998. 84. G. Chen, L. Gong, B.C. Giovanella, J.R. Chen and D. S-L. Chow, Liposomal camptothecin with improved lactone-moiety stability and enhanced antitumor activity. Presented in the 25th International Symposium on Controlled Release of Bioactive Materials, Las Vegas, Nevada, June 1998. 85. L. Gong, B.C. Giovanella and D. S-L. Chow, Improved lactone stability of 9-nitro -camptothecin in vitro and in vivo by liposomal formulation. Presented in 89th Annual Meeting of AACR, New Orleans, Louisiana, March 1998. 86. D.S-L. Chow, G. Chen, L. Gong and B.C. Giovanella, Liposomal camptothecin and 9-nitro-

camptothecin: Formulation, pharmacokinetics and preclinical antitumor activity. Presented in the 24th International Symposium on Controlled Release of Bioactive Materials (Abstract #6520), Stockholm, Sweden, June 1997.

87. L. Gong, B.C. Giovanella and D. S-L. Chow, High-performance liquid chromatographic assay of 9-nitro-camptothecin in rat plasma and tissues. Presented in 12th National Meeting, AAPS, Boston, Massachusetts (Abstract: APQ 366), November 1997. 88. D.S-L. Chow, S. Phadungpojna, T. Williams and B.S. Andersson, Multiple-dosing pharmacokinetics of parenteral busulfan in murine model. Presented in the 88th Annual Meeting of AACR, San Diego, CA (Abstract #11), April 1997.

D. S-L. Chow

5/9/2012 34

89. B.S. Andersson, T. Madden, W. Hu, D. S-L. Chow, K. Blume, T.E. Williams, B. Spilker, W.P. Vaughan, R.E. Champlin, Phase I-II study of IV busulfan/cyclophosphamide (BuCy) as stem cell transplantation conditioning therapy. Presented in the 88th Annual Meeting of AACR, San Diego, CA (Abstract #1499), April 1997.

90. D.S-L. Chow, G. Chen, L. Gong and B.C. Giovanella, Pharmacokinetics and in vivo antitumor activity of liposomal encapsulated camptothecin and its analog. Presented in the 88th Annual Meeting of AACR, San Diego, CA (Abstract #1733), April 1997. 91. S. Phadungpojna, L. Gong, T. Williams, B.S. Andersson and D. S-L. Chow, Comparative biodistribution profiles of busulfan in rats after intravenous and oral administrations. Presented in the 2nd Annual Scientific Meeting of the American Society for Blood and Marrow Transplantation (ASBMT), San Diego, CA, October 1996. 92. B.S. Andersson, T. Madden, W. Hu, D. S-L. Chow, K. Blume, T.E. Williams, W.P. Vaughan, R.E. Champlin, IV busulfan and cyclophosphamide as pretransplant conditioning therapy: A phase one and pharmacokinetic study. Presented in the 2nd Annual Scientific Meeting of the ASBMT, San Diego, CA, October 1996. 93. G. Chen and D. Chow, Detection of camptothecin in biological samples by reversed-phase

liquid chromatography, Presented in the 11th National Meeting, AAPS, Seattle, Washington, (Abstract: APQ 1125), October 1996.

94. L. Gong, G. Chen, B.C. Giovanella and D. S-L. Chow, Development and characterization

of liposomal formulation of 9-nitro-camptothecin. Presented in the 11th National Meeting, AAPS, Seattle, Washington, (Abstract: PT 6021), October 1996.

95. R.O. Kumi, Y.Y. Zou, D.S-L. Chow and R. Perez-Soler, In vitro evaluation of “stealth” and conventional liposomal annamycin formulations. Presented in the 11th National Meeting, AAPS, Seattle, Washington, (Abstract: PT 6031), October 1996. 96. G. Chen, J.A. Double, M. Bibby and D. Chow, Characterization of liposomal mimetic formulations for selective targeting. Presented in the 11th National Meeting, AAPS, Seattle,

Washington, (Abstract: PT 6019), October 1996. 97. A.O. Nornoo, D.W. Osborne and D.S-L. Chow, Microemulsion formulations as oral drug

delivery systems. Presented in the 11th National Meeting, AAPS, Seattle, Washington, (Abstract: PT 6243), October 1996.

98. S. Phadungpojna, B.S. Andersson, T. Williams and D.S-L. Chow, Preclinical pharmacokinetics and pharmacodynamics of parenteral busulfan in dogs. Presented in

the 11th National Meeting, AAPS, Seattle, Washington, (Abstract: PPDM 8351), October 1996.

99. G. Chen, B.W. Barry and D. Chow, Pharmacokinetic evaluation of liposomal camptothecin. Presented in the 11th National Meeting, AAPS, Seattle, Washington, (Abstract: PPDM

D. S-L. Chow

5/9/2012 35

8345), October 1996. 100. S. Phadungpojna, D.S-L. Chow, D.T. Reardan, R.E. Champlin, B.S. Andersson, Pharmacokinetics and toxicity of parenteral busulfan in dogs. Presented in the 87th Annual Meeting of AACR, Washington, DC, (Abstract: #2528), April 1996. 101. B.S. Andersson, T. Madden. W. Hu, D. Chow, W.P. Vaughn, K. Blume, T.F. Williams, R.E. Champlin, Phase one study of intravenous (i.v.) busulfan (Bu) and cyclophosphamide (Cy) as pretransplantation conditioning therapy. Presented in the 37th Annual Meeting, American Society of Hematology, Seattle, Washington, (Blood, 86D:#863), December 1995. 102. D. Liang, M.Y Huang, D. Heald and D. Chow, Simultaneous analysis of estradiol, estrone, norethindrone and norethindrone acetate for drug release and transdermal permeation evaluations. Presented in the 10th National Meeting, AAPS, Miami, FL, (Abstract: APQ

1006), November 1995. 103. S. Phadungpojna, B.S. Andersson, T. Williams and, D. Chow, HPLC assay of busulfan for organ distribution evaluation in rats. Presented in the 10th National Meeting, AAPS, Miami,

FL, (Abstract: APQ 1071), November 1995. 104. R.O. Kumi, Y. Zou, D. Chow and R. Perez-Soler, Development and characterization of a liposomal annamycin formulation using polyethylene glycol derivatized lipid. Presented in the 10th National Meeting, AAPS, Miami, FL, (Abstract: PDD 7274), November 1995. 105. G. Chen, R. Pasricha and D. Chow, Characterization of liposomal mimetic formulation for lymphotropic delivery, Presented in the 10th National Meeting, AAPS, Miami, FL, (Abstract:

PDD 7275), November 1995. 106. D. Liang, D. Chow and C. White, Increase therapeutic efficacy of cefazolin encapsulated

in a liposomal carrier against S. sureus infection in mice. Presented in the 10th National Meeting, AAPS, Miami, FL, (Abstract: PDDM 8318), November 1995.

107. D. Liang, C.A. White and D. Chow, Improved targeting and therapeutic efficacy of

cefazolin encapsulated in liposomes against S. aurens in mouse infection model. Presented in the 22nd International Symposium on Controlled Release of Bioactive Materials, Seattle, Washington, (Conference Proceedings, pp. 448-449), August 1995.

108. D. Liang, D. Chow and C. White, Comparative pharmacokinetics and tissue

distribution studies of liposomal cefazolin in normal and neutropenic rats. Presented in the 9th National Meeting, AAPS, San Diego, CA, (Abstract: PPDM 8313), November 1994.

109. G. Chen and D. Chow, Organ targeting of Zidovudine. Presented in the 9th National

Meeting, AAPS, San Diego, CA, (Abstract: PPDM 8473), November 1994.

D. S-L. Chow

5/9/2012 36

110. S. Phadungpojna, H. Bhagwatwar, B. Andersson and D. Chow, Development of an intravenous formulation of busulfan: Accelerated Stability testing. Presented in the 9th National Meeting, AAPS, San Diego, CA, (Abstract: PPDM 7401), November 1994.

111. D. Chow and G. Chen, Liposomal targeting of Zidovudine. Presented in the 21st

International Symposium on Controlled Release of Bioactive Materials, Nice, France, (Conference Proceedings, pp. 150-151), June 1994.

112. H. Bhagwatwar, B. Andersson and D. Chow, Comparative pharmacokinetics of

intravenous and oral busulfan in rats. Presented in the 85th Annual Meeting of AACR, San Francisco, CA, (Abstract: #1772), April 1994.

113. G. Chen and D. Chow, Targeted delivery of Zidovudine. Presented in AAPS

Western Regional Meeting, San Francisco, CA, March 1994. 114. H. Bhagwatwar, B. Andersson and D. Chow, In vitro and in vivo evaluations of

intravenous busulfan formulation. Presented in the 8th National Meeting, AAPS, Orlando, FL, (Abstract: PDD 7063), November 1993.

115. G. Chen and D. Chow, Liposomal formulation of zidovudine - In vitro and in vivo

characterization. Presented in the 8th National Meeting, AAPS, Orlando, FL, (Abstract: PDD 8063), November 1993.

116. H. Bhagwatwar, D. S-L. Chow and B.S. Andersson, Formulation and Pharmaco-

kinetics of intravenous busulfan in rats. Presented in the 84th Annual Meeting of AACR, Orlando, FL. May 21, 1993.

117. H. Bhagwatwar, B.S. Andersson and D.S-L. Chow, Development of intravenous

formulation of busulfan. Presented in the 7th National Meeting, AAPS, San Antonio, Texas, (Abstract: PDD 7127), November 1992.

118. G. Chen and D. S-L. Chow, Formulation of Zidovudine. Presented in the 7th

National Meeting, AAPS, San Antonio, Texas, (Abstract: PDD7295), November 1992.

119. L. Wongpayapkul and D. Chow, Comparative evaluation of various enhancers on the

transdermal permeation of propranolol hydrochloride. Presented in the 6th National Meeting, AAPS, Washington, D.C., (Abstract: PDD 7053), November 1991.

120. S.W. J. Lau, L. Wongpayapkul, W.P. Pfister, S. Feldman and D. Chow, Release and

transdermal permeation profiles of physostigmine and tetrahydroaminoacridine from two pressure sensitive silicone adhesives. Presented in the 6th National Meetings, AAPS, Washington, D.C., (Abstract: PDD 7321), November 1991.

121. T.I. Wang, J.R. Chen and D. Chow, Pharmacokinetics of mitomycin C (MMC)

administrated as a phospholipid dispersion. Presented in the 6th National Meeting,

D. S-L. Chow

5/9/2012 37

AAPS, Washington, D.C., (Abstract: PDD 8143), November 1991. 122. S. Sista, D. Tang-Liu and D. Chow, Transdermal permeation, disposition and bioconversion of AGN 190168 from a gel formulation using human fresh skin and

fuzzy rat skin as barriers. Presented in the 5th National Meeting, AAPS, Las Vegas, Nevada, (Abstract: PDD7007), November 1990.

123. T.I. Wang, J.R. Chen and D. Chow, Sustained release formulations of Mitomycin C.

Presented in the 5th National Meeting, AAPS, Las Vegas, Nevada, (Abstract: PDD7212), November 1990.

124. J. Shah, I. Kaka, J. Lau, S. Tenjarla and D. Chow, The Lag-time in diffusion as

applied to transdermal drug permeation. Presented in the 5th National Meeting, AAPS, Las Vegas, Nevada, (Abstract: PDD7308), November 1990.

125. S.N. Tenjarla and D. Chow, Characterization of skin permeation kinetics of ionized

and unionized species of propranolol. Presented in the 5th National Meeting, AAPS, Las Vegas, Nevada, (Abstract: PDD7305), November 1990.

126. K.A. Kumi, D. Chow and C.A. White, Pharmacokinetics of two liposomal

cefotaxime formulations. Presented in the 5th National Meeting, AAPS, Las Vegas, Nevada, (Abstract: PPDM8122), November 1990.

127. S.N. Tenjarla and D.S-L. Chow, Propranolol transdermal delivery. Presented in the

4th National Meeting, AAPS, Atlanta, GA, (Abstract: PD834), October 1989. 128. S.W. J. Lau, D. Chow and S. Feldman, Transdermal permeation characteristics of

physostigmine and tetrahydroaminoacridine. Presented in the 4th National Meeting, AAPS, Atlanta, GA, (Abstract: PD1178), October 1989.

129. K.A. Kumi, D. Chow and C.A. White, Optimization of a liposomal dosage

formulation for beta-lactam antibiotics. Presented in the 4th National Meeting, AAPS, Atlanta, GA, (Abstract PD868), October 1989.

130. J. Shah, J.R. Chen and D. Chow, Bioavailability and in situ absorption study of

etoposide. Presented in the 3rd National Meeting, AAPS, Orlando, FL, (Abstract: PD 932), November 1988.

131. S.N. Tenjarla and D. Chow, Effect of enhancers on permeation of propranolol

through hairless mouse and human cadaver skin. Presented in the 3rd National Meeting, AAPS, Orlando, FL, (Abstract: PD 985), November 1988.

132. S.W. J. Lau, D. Chow and S. Feldman, Development of an HPLC assay for

transdermal permeation study of physostigmine and tetrahydroaminoacridine. Presented in the 3rd National Meeting, AAPS, Orlando, FL, (Abstract: PD 1025), November 1988.

D. S-L. Chow

5/9/2012 38

133. D. Chow, S. Tenjarla, M. Tsui, S. Asici and D. Hsieh, Structure activity relationship of

enhancers with enhancing strength on drug permeation and structural perturbation in stratum corneum. Presented in the 15th International Symposium on Controlled Release of Bioactive Materials, Basel, Switzerland, (Conference Proceedings, pp. 85-86), August 1988.

134. D. Chow, M. Tsui and D. Hsieh, Differential effects of transdermal permeation

enhancement with a new enhancer C1B-1 and Azone. Presented in Japanese-United Sates Joint Conference (JUC) Pharm. Sci. '87, Honolulu, Hawaii, (Abstract: 49), December 1987.

135. T.I. Wang, J.R. Chen and D. Chow, Liposomal formulations of Mitomycin C. Presented in

JUC Pharm. Sci. '87, Honolulu, Hawaii, (Abstract: 306), December 1987. 136. J. Shah, J.R. Chen and D. Chow, Oral bioavailability of etoposide from co-precipitate

with PEG 8000 and solution. Presented in JUC Pharm. Sci. '87, Honolulu, Hawaii, (Abstract: 95), December 1987.

137. J. Shah, J.R. Chen and D. Chow, Physico-chemical properties of etoposide

polymorph. Presented in JUC Pharm. Sci. '87, Honolulu, Hawaii, (Abstract: 297), December 1987.

138. S.N. Tenjarla and D. Chow, Development of HPLC assay of propranolol for

transdermal permeation study. Presented in JUC Pharm Sci. '87, Honolulu, Hawaii, (Abstract: 59), December 1987.

139. D. Chow, N. Etim, M. Tsui and S. Tenjarla, Comparative permeation of drugs

through human skin and hairless mouse skin under the influence of penetration enhancer. Presented in the 14th International Symposium on Controlled Release of Bioactive Materials, Toronto, Ontario, Canada, (Conference Proceedings, pp. 105-106), August 1987.

140. D. Chow, T.I. Wang and J.R. Chen, Liposomal formulations of Mitomycin C.

Presented in FASEB Summer Research Conference, Saxtons River, Vermont, June 1987.

141. J.C. Shah, D.S-L. Chow, Assay and preformulation study of anticancer drug-

etoposide. Presented in the 1st National Meeting, American Association of Pharmaceutical Scientists (AAPS), Washington DC, (Abstract: 63), November 1986.

142. D.S.T. Hsieh, F.S. Hwu and D.S-L. Chow, Determination of release rates of unstable

compounds from devices. Presented in the 13th International Symposium on Controlled Release of Bioactive Materials, Norfolk, Virginia, (Conference Proceedings: pp. 65-66), August 1986.

D. S-L. Chow

5/9/2012 39

143. D.S-L. Chow, Evaluation of Azone, a new percutaneous penetration enhancer: Its enhancement kinetics, mechanisms and potential cellular effects on cultured dermal fibroblasts. Presented in the Texas Women Scholars Symposium: Contemporary Perspective, Austin, Texas, April 1986.

144. D.S-L. Chow, Azone effects on the cell proliferation kinetics and morphology of

cultured human and mouse L-929 dermal fibroblasts. Presented in the 38th National Meeting, APhA Academy of Pharmaceutical Sciences, Minneapolis, Minnesota, (Abstract: 80), October 1985.

145. X.S. Sun, D. Chow, K. Embil and C. Lee, Phenprobamate kinetics in rats. Presented

in the 132nd Annual Meeting, American Pharmaceutical Association, San Antonio, TX, (Abstract: 112), February 1985.

146. D. S-L. Chow, X.S. Sun, T.I. Wang, K. Embil and C.S. Lee, HPLC analysis of

phenprobamate and acetaminophen in rat serum. Presented in the 37th National Meeting, APhA Academy of Pharmaceutical Sciences, Philadelphia, PA, (Abstract: 217), October 1984.

147. D.S-L. Chow, Relative intrinsic activities of budesonide to other glucocorticoids:

Inhibitions of cell proliferation and DNA synthesis in cultured L-929 dermal fibroblasts. Presented in the 131st Annual Meeting, APhA, Montreal, Quebec, Canada, (Abstract: #5, p. 95), May 1984.

148. T.I. Wang, D. Hsieh and D.S-L. Chow, Controlled-release topical polymeric

formulations of anthralin. Presented in the 131st Annual Meeting, , APhA, Montreal, Quebec, Canada, (Abstract: #6, p. 95), May 1984.

149. D.S-L. Chow and I. Kaka, Effect of Azone, 1-dodecylazacycloheptan-2-one, on

percutaneous penetration kinetics of topical glucocorticoid. Presented in the 130th Annual Meeting, APhA, New Orleans, Louisiana, (Abstract: #30, p. 50), April 1983.

150. C.S. Lee, H.O. Senekjian, T.H. Kuo, D.S-L. Chow and R. Krothapalli, Absorption

and disposition of ibuprofen in hemodialyzed uremic patients. Presented in the Annual Meeting of the American College of Clinical Pharmacology, Washington, D.C., April 1983.

151. D.S-L. Chow, T.H. Kuo, B. Mederski-Samoraj and C. Lee, Pharmacokinetics of

ibuprofen in nephrectomized dogs. Presented in the 129th Annual Meeting, APhA, Las Vegas, (Abstract: #60, p. 53), Las Vegas, Nevada, April 1982.

152. D.S-L. Chow, J.O. Runikis and Wm. D. Stewart, Nuclear retention of triamcinolone

acetonide in cultured dermal fibroblasts upon prolonged incubation. Presented in the 129th Annual Meeting, APhA, Las Vegas, Nevada, (Abstract: #61, p. 53), April 1982.

153. D.S-L. Chow, J.O. Runikis and Wm. D. Stewart, Sites of localization of topical

D. S-L. Chow

5/9/2012 40

glucocorticoids in the nuclei of cultured fibroblasts. Presented in A.F.P.C. Research Conference, Winnipeg, Mannitoba, May 1981.

154. J.O. Runikis, R. Biswas, D.S-L. Chow and Wm. D. Stewart, Stabilization of the

double-stranded helix of DNA by glucocorticoids. Presented in A.F.P.C. Research Conference, Victoria, B.C., 1978. (Abstract), Canadian Journal of Pharmaceutical Sciences, 13(4):100, 1978.

155. Y.K. Tam, D.S-L. Chow and F.S. Abbott, An improved GLC-FID assay of

acetylsalicylic and salicylic acids. Presented in A.F.P.C. Research Conference, Victoria, B.C., 1978. (Abstract), Can. J. Pharm. Sci.,13(4):103, 1978.

156. D.S-L. Chow, J.O. Runikis and F.S. Abbott, Determination of hydrocortisone and

triamcinolone acetonide in tissue culture by gas-liquid chromatography. Presented in A.F.P.C. Research Conference, Victoria, B.C., 1978. (Abstract), Can. J. Pharm. Sci., 13(4):101, 1978.

D. S-L. Chow

5/9/2012 41

TEACHING ACTIVITES I. Graduate and Professional Courses I-A. Design and development of new courses/laboratories: 1. PCEU/PCOL 7350 Laboratory Methods in Pharmaceutical Research 1996

(small animal surgery, liquid scintillation counting, thermal analysis and tissue culture techniques)

2. PCEU/PCOL 7297 Research Methods Discussion 1996 I-B. Major revision of existing courses: 1. PHAR 5432 Pharmacokinetics, 1996 2. PHAR 5332 Pharmacokinetics, 2004 I-C. Coordinator of the following courses: Graduate Courses PCEU 6341 Advanced Pharmacokinetics PCEU 6397 Regulatory Affairs PCEU 6345 Advanced Physical Pharmacy and Drug Delivery Systems II PCEU/PCOL 7297 Research Methods Discussion PCEU 7340 Advanced and Innovative Drug Delivery Professional Courses PHAR 5432 Pharmacokinetics (1991-4; 1996-2004) PHAR 5332 Pharmacokinetics (2004 -) I-D. Lecturing the following courses: Graduate Courses PCEU/PCOL 7350 Laboratory Methods in Pharmaceutical Research PCOL 7433 Recent Advances in Pharmaceutical Sciences PCEU 6341 Advanced Pharmacokinetics PCEU 6242 & 6243 Literature Review PCOL 6371 Advanced Pharmacology I (on Pharmacokinetics; 2005-07 )

D. S-L. Chow

5/9/2012 42

Professional Courses PCEU 3340 Pharmaceutical Dosage Forms I PCEU 3341 Pharmaceutical Dosage Forms II PCEU 4341 Dispensing Pharmacy I-E. Continuing Education “New Dosage Forms and Drug Delivery Systems”. Continuing Education Program, College of Pharmacy, University of Houston, March 19 - April 17, 1985 II. Supervision of Graduate Students and Post-Doctoral Fellows, and Serving on Dissertation Committees II-A. As Major Advisor II-A-1. Ph.D. Students Graduated:

1. Roland Ako June 2011 (Pharmd/PhD) Dissertation Title: Pharmacokinetics/Pharmacodynamics (PK/PD) of Oral

Diethylstilbestrol (DES) in Recurrent Prostate Cancer Patients and of Oral Dissolving Filem (ODF)-DES in Rats

2. Fady Ibrahim April 2011

Dissertation Title: Formulations of Lazaroid-U74389G for Organ Targeting and Potential Chemotherapy

Current Position: Postdoctoral Associate, University of British Columbia, B.C., Canada (2011-)

3. Rania Haddadin November 2010

Dissertation Title: Combination of Manumycin A and Mebendazole in Human Breast Cancer Cell Lines

4. Ting Zhu May 2009 Dissertation Title: Sustained Delivery of Hydrophilic Cefazolin Using

Poly (lactic-co-glycolic acid) Microspheres - Formulations, Pharmacokinetics and In Vitro-In Vivo

Correlations Current Position: Senior Formulation Scientist, Celgene- AbraxisBio (2009-) 5. Elimika Pfuma May 2009 (PharmD/PhD) Dissertation Title: Pharmacokinetics and Pharmacodynamics of Combination

CZ48 and Manumycin A in an Athymic Mouse Model Current Position: Clinical Pharmacologist, Biopharmaceutics Reviewer. FDA

D. S-L. Chow

5/9/2012 43

(2009-) 6. Yulan Qi May 2008

Dissertation Title: Impact of size on Pharmacokinetics and Biodistributions of mebendazole nanoformulations in mice and rats

Current Position: Preclinical/Clinical Pharmacokineticist, BioMarin (2008-) 7. Yousif Rojeab June 2007

Dissertation Title: Microemulsion Formulations of CZ48, lactone-stabilized camptothecin-C20-propionate, for transdermal delivery

Current Position: Assistant Professor, Ohio Northern University (2007-) 8. Pranav Gupta June 2006

Dissertation Title: Oral bioavailability enhancement of mebendazole from self nanoemulsifying drug delivery system (SNEDDS) and self emulsifying drug delivery system (SEDDS) and particle size effects on mebendazole disposition from parenteral formulations

Current Position: Senior Formulation Scientist, Schering-Plough (2006-2010) Senior Formulation Scientist, Merck (2010-)

9. Monica Chuong November 2004

Dissertation Title: Pharmaceutical stability of Nitro-Dur transdermal patches, Topicort emollient cream and traiamcinolone acetonide

cream after flown aboard space shuttles or the internal space station

Current Position: Associate Professor (2012-), Assistant Professor (2006-12), Massachusetts College of Pharmacy

Previous Position: Postdoctoral Associate, Oregon State University (2004-6) 10. Xiaohui Li July 2004

Dissertation Title: Preclinical pharmacokinetics of CZ48, lactone-stabilized camptothecin, in rats and its potential routes of administration for therapy

Current Position: Associate Director, Clinical Pharmacology, BMS (2012-) Previous Position: Associate Research Investigator Pharmacokineticist (2008-

2010), Group Leader, Abbott (2010-2012) Senior Preclinical/Clinical Pharmacokineticist,

Pharmaceutical Products Development (2004-2008) 11. Jie Ling October 2001

Dissertation Title: Preclinical pharmacokinetics and biodistribution of polynitroxyl albumin (PNA) in rats using electron

paramagnetic resonance (EPR) for drug monitoring Current Position: Principal Clinical Pharmacokineticist, Centocor (2006-)

Previous Positions: Clinical Pharmacokineticist, Genetec (2005-06) Clinical Pharmacokineticist, Protein Design Lab (2004-05)

D. S-L. Chow

5/9/2012 44

Preclinical and Clinical Pharmacokineticist, Pfizer (2001-04) 12. Adwoa Nornoo December 1998 Dissertation Title: Development and pharmacokinetic/pharmacodynamic

evaluations of intravenous microemulsions of paclitaxol Current Position: Associate Professor, Palm Beach Atlantic University (2008-)

Previous Positions: Assistant Professor, Albany University (2001-2008) Lecturer, Texas Southern University (1999-2001) 13. Ling Gong August 1998

Dissertation Title: Development of 9-nitro-camptothecin liposomal formulation: Preformulation, pharmacokinetics, biodistribution and antitumor activity in rats and mice

Current Position: CEO, Healthon Inc. (1999-) Previous Position: Postdoctoral Associate with Dr. Chow, UH (1998-99)

14. Sasima Phadungpojna December 1997

Dissertation Title: Preclinical pharmacokinetics and pharmacodynamics of busulfan with intravenous administration of a newly developed parenteral formulation

Current Position: Research Fellow, Johnson & Johnson (2012-) Previous Positions: Senior Manager, Process Development, Cephalon (2004-2012)

Principal Tech Support Specialist, Schering-Plough (2002-04) Research Scientist, Whitehall Robins International (1998-02) 15. Robert Kumi November 1997

(Co-advisor with Dr. Perez-Solar, M.D. Anderson Cancer Center) Dissertation Title: Formulation development, preclinical pharmacokinetics and

efficacy of liposomes incorporating of annamycin, a lipophilic analog of doxorubicin

Current Position: Director, Clinical Development/Lead Regulatory Scientist, Tolmar, Inc. (2010-present) Previous Position: Biopharmaceutics Reviewer, FDA (1999-2010)

Postodoctoral Associate, ViroTex (97-99) 16. Harshal Bhagwatwar August 1995

Dissertation Title: Development of intravenous formulation of busulfan: Preformulation, formulation and pharmacokinetic evaluation

Current Position: Research Scientist, Pharmaceutical Education and Research Development Institute, India (1995-)

17. Dong Liang August 1995 (Co-advisor: Dr. C. White)

Dissertation Title: Liposomal formulation of cefazolin Current Position: Chair (2007-), Professor (2010-),

Texas Southern University (TSU) Previous Positions: Associate Professor (2004-2010)

D. S-L. Chow

5/9/2012 45

Assistant Professor, (1998-2004), TSU Pharmacokinetist, Mylan Pharmaceuticals. (1997-98) Research Associate, TSU (1995-97) 18. Geneva Chen May 1995

Dissertation Title: Sustained-release and lymphotropic liposomal mimetic formulation of zidovudine – Formulation and pharmacokinetics and organ distribution evaluations

Current Position: Consultant, Professional Compounding Centers of America (PCCA; 1999-)

Previous Positions:Senior Research Scientist, Aronex (1998-9) Research Assoc. with D. Chow, and Lecturer, UH (1996-98) Lecturer, Univ. Bradford, UK (1995-96) 19. Kofi Kumi April 1993 (Co-advisor: Dr. C. White)

Dissertation Title: Development of evaluation of liposomal formulation of beta- lactam antibiotics Current Position: Biopharmaceutics Reviewer, FDA (1994-)

20. Johnny Lau July 1992 (Co-advisor: Dr. Feldman)

Dissertation Title: Development of transdermal therapeutic system for physostigmine and tetrahydroaminoacridine Current Position: Senior Clinical Pharmacologist, Biopharmaceutics Reviewer.

FDA (1998-) Previous Position: Senior Scientist, Proctor & Gamble Pharm.(1992-98)

21. Tsu-I Wang December 1991

Dissertation Title: Sustained release formulation of mitomycin C – Formulation development and in vitro and in vivo evaluations

Current Position: Consultant, PCCA (1993-present) Previous Position: Visiting Assistant Professor, UH (1991-93)

22. Srinivas Tenjarla November 1989

Dissertation Title: Transdermal delivery of propranolol: Preformulation and prototype fabrication study

Current Position: Senior Director, Shire Pharmaceutical (2003-) Previous Positions: Director, Berlex Pharmaceutical (2001-03)

Research Scientist III, Southern Research Institute (1998-2001)

Associate Professor (95-98), Assistant Professor (90-95) Mercer University, Georgia 23. Jaymin Shah December 1988

Dissertation Title: Preformulation and formulation of an oral dosage form of etoposide

Current Position: Research Fellow (2006-), Pfizer (1999-)

D. S-L. Chow

5/9/2012 46

Previous Positions: Associate Prof. (94-99), Assistant Prof. (89-94) Medical University of South Carolina M.S. Students Graduated: 1. Rajni Pasricha December 1995

Thesis Title: Characterization of liposomal mimetic formulation for lymphotropic delivery

Current Position: Registered Pharmacist

2. Sasima Phadungpojna August 1995 (Ph.D. in December1997) Thesis Title: Stability of busulfan intravenous formulation and its stock solution in cosolvent mixture of dimethyacetamide and polyethylene

glycol 400 Current Position: Senior Manager, Process Development, Cephalon (2004-)

3. Ling Gong December 1994 (Co-advisor with Dr. C. White);

(Ph.D. in August 1998) Thesis Title: Liposomal formulation and its effects on pharmacokinetics

and tissue distribution of ampicillin Current Position: CEO, Healthon Inc. (1999-)

4. Wei Chen October 1994 (Co-advisor with Dr. G. Lopez-Berestein)

Thesis Title: Identification and characterization of mannose receptor in leukemia cell lines

Current Position: Research Scientist, M. D. Anderson Cancer Center (1994-)

5. Inyang Etim December 1987 Thesis Title: Comparative transdermal permeation disposition and

enhancing effects of Azone in human cadaver skin and hairless mouse skin

Current Position: Pharm D. and Associate Professor, Assistant Professor (1996), Texas Southern University (1996-)

6. Tsu-I Wang December 1984 (Ph.D. in December 1991)

Thesis Title: Controlled-release topical polymeric formulation of anthralin Current Position: Consultant, PCCA (1993-present)

7. Idris Kaka May 1984

Thesis Title: Effect of 1-dodecylazacycloheptan-1-one (Azone) on percutaneous penetration kinetics of triamcinolone acetonide and its possible mechanisms

Current Position: Scientist, Nelson Co., CA

D. S-L. Chow

5/9/2012 47

II-A-2. Current Graduate Students in Progress :

1. Jojo (Jie) He Pursuing Ph.D. 2007-present

(Co-advisor with Dr. Vincent Tam) Dissertation Project Title: Pulmonary delivery of polymaxin B for enhanced efficacy

in a pneumonia mouse model

2. Angela (Yang) Teng Pursuing Ph.D. 2008-present

Dissertation Project Title: Clinical pharmacokinetics and pharmacodynamics of riluzole in patients with traumatic acute spinal cord injury

3. Stanley Hsiao Pursuing Ph.D. 2008- present (Co-advisor with Dr. Dong Liang at Texas Southern University)

Dissertation Project Title: Pharmacokinetics of propofol and hydrophilic prodrug in obese pediatric patients and in Zucker rat model

4. Dong Dong Pursuing Ph.D. 2009-present Dissertation Project Title: Parenteral delivery of nanosuspension of CZ48 for lung

cancer mouse model-pharmacokinetics and efficacy 5.Tanay Samant Pursuing Ph.D. 2009-present

Dissertation Project Title: Development of sustained depot of diethylstilbesterol and pharmacokinetics/pharmacodynamics in mouse models

6. Lei Wu Pursuing Ph.D. 2010-present

Dissertation Project Title: Pharmacokinetics and pharmacodynamics of intranasl scopolamine for NASA missions

7. Zhiyi Cui Pursuing Ph.D. 2010-present

Dissertation Project Title: Pharmacokinetics and pharmacodynamics of dexmedetomidine in pregnant ewes and fetuses

8. Lili Cui Pursuing Ph.D. 2011-present (Co-advisor with Dr. Chun Li at M.D. Anderson Cancer Center) Dissertation Project Title: Nanoparticles for multimodality molecular imaging in

cancer diagnosis and therapy

9. Prajakta Gadgil Pursuing Ph.D. 2012-present Dissertation Project Title: Brain targeting of Lazaroid-U74389G for glioblastoma 10. Daping Zhang Pursuing Ph.D. 2012-present

Dissertation Project Title: Transdermal delivery of vitamin D derivative for Alzeimer disease

D. S-L. Chow

5/9/2012 48

11. Chia-Wen Lee Pursuing Ph.D. 2012-present Dissertation Project Title: Clinical pharmacokinetics of antidepressants in bariatric patients

II-A-3. Postdoctoral Fellows:

1. Yang Wang 2011-Present, as Research Associate Professor Faculty of Northeast Forestry University, Harbin, China

2. Janice Tsai 2010-2011, Faculty of Cheng Kung University, Taiwan

3. Tina (Li) Zhang 2008-2009, Faculty of Shandong University, China 3. Johnny Lau September, 2008 Senior Clinical Pharmacologist, FDA Short-term Sabbatical Program 4. Gopal Pillai 2007, Faculty of University of West Indies, Trinidad.

5. Jing Ma 2004-present

6. Enze Wang 2003-2004

7. Wei Jiang 2002-2004

8. Adwoa Nornoo 1999

9. Ling Gong 1998-1999

10. Geneva Chen 1996-1998

11. Ladda Wongpayapkul 1991-1992, Faculty of Chiang Mai University, Thailand

12. Sevil Asici 1988-1989, Faculty of Ege University, Istanbul, Turkey

II-A-4. Professional students for research elective

Farah Javid-Majd Summer 2011 Louisa Teng Fall 2010 Chinonyerem Igboagi Spring, Summer 2010 Cristina Johnston Fall 2008

Shanhana Quadin Fall 2006 Bao Trinh Fall 2006 Diana Thai Summer 2006

D. S-L. Chow

5/9/2012 49

Thuy F. Nguyen Spring, Summer and Fall 2005 Leah Cho Summer 2003 Thuy D. Nguyen Summer 2002

Milind Patel Summer 2000 Ann Lu Summer 2000 Jun Zhu Summer 2000 Eugene Olewe Spring 2000

Jamie Hampton Summer 1999 Yen-Tuyet Hua Spring 1998 (Doctor of Pharmacy Experiential Rotation) Ann Ukonu Fall 1995 II-A-5. College students for summer internship Daniel N. Wang Cornell University Summer 2007 Daniel G. Hwang Vanderbilt University Summer 2007 Michael Ho UH- Bioengineering Summer 2006 II-B. Member of Thesis/Dissertation Committees Name Degree Date Advisor 1. Miao Huang Ph.D. July 2009 Dr. Chun Li (MDACC) –Oct 2011 UT-GSBS, Experimental Diagnostic Imaging 2. Katrina Leyden Ph.D. May 2009- Dr. Sandy Hanneman UT-Nursing School 3. Kristina Leyden Ph.D. May 2009- Dr. Sandy Hanneman UT-Nursing School 4. Annirudha Chillar Ph.D. 2008-2010 Dr. Ke-He Ryan UH College of Pharmacy 5. Baojian Wu, Ph.D. Ph.D. 2010-2012 Dr. Ming Hu UH College of Pharmacy 6. Zhen Yang Ph.D. 2009-2012 Dr. Ming Hu UH College of Pharmacy 7. Limin Zhou Ph.D. August 08 Dr. Joan Z. Zuo (as External Examiner) Chinese University of Hong Kong

D. S-L. Chow

5/9/2012 50

8. Cindy Anne M.S. April 2008 Dr. Gopal Pillai Bhagwadin (as External Examiner) University of West Indies 10. Wendy Jiang Ph.D. Jan 2008 - 2011 Dr. Ming Hu 11. Rashim Singh Ph.D. Sept 2007 - 2010 Dr. Ming Hu 12. Kaustubh Kulkarni Ph.D. Sept 07 – Aug 08 Dr. Ming Hu (declined to serve further) 13. Rui Zhang Ph.D. Sept 2007 - 2011 Dr. Chun Li (MDACC) UT-GSBS, Experimental Diagnostic Imaging 14. Wei Zhu Ph.D. Nov 2008 Dr. Ming Hu 15. Stephen Wang Ph.D. Dec 2006 Dr. Ming Hu 16. (Toyin) Olutoyin M.S. June 2006 - 2011 Co-mentor with Dr. Dean

Olutoye, M.D. Andropoulos Clinical Scientist Training Program, Baylor College of Medicine

17. Jeremy Strauch Ph.D. Dec. 04 -05 Dr. Ramanan Krishnamoorti

(Discontinued in pursuit) (Chem. Eng, UH) 18. Yuan Gao Ph.D. March 05 Dr. Albert Chow (as External Examiner) Chinese University of Hong Kong 17. Emmanuelle Cruze M.S. May 02 Drs. Mohanty/ Krishnamoorti

(Chem. Eng, UH)

19. Jamie Renbarger, MD M.S. Sept 01 Texas Children Hospital -July 02 Clinical Investigation in Pediatric Oncology 20. Ali Azhdarinia, M.S. Ph.D. Sept 01-03 Dr. David Yang (Discontinued in pursuit) M.D. Anderson Cancer Center 21. Lisa Bomgaars, MD M.S. Sept 00 Dr. Susan Blaney -Feb 07 Texas Children Hospital Clinical Investigation in Pediatric Oncology

D. S-L. Chow

5/9/2012 51

22. Xiaoxia Wen M.S. July 00 Dr. Chun Li M.D. Anderson Cancer Center 23. Rhonda Rippley Ph.D. Aug. 96 Dr. C.L. Strokes

(Chem Eng. UH) 24. Bala Krishnamurthy M.S. Feb. 96 Dr. C. Eick(Computer Sci, UH) 25. Ashish Shah M.S. May 95 Dr. C. Eick (Computer Sci, UH) 26. Mary Mathew Ph.D. Dec. 94 Dr. Das Gupta, Pharmaceutics UH College of Pharmacy 27. Ann Berry Ph.D. Aug. 91 Dr. Feldman, Pharmaceutics UH College of Pharmacy 28. Sury Sista Ph.D. May 90 Dr. Feldman, Pharmaceutics 29. Xin-Sheng Sun Ph.D. May 88 Dr. Feldman, Pharmaceutics 30. Niranjan Rao Ph.D. Dec. 87 Dr. Feldman, Pharmaceutics 31. Ling Hui Chow M.S. May 85 Dr. Lee, Pharmaceutics UH College of Pharmacy 32. Vipool Patel M.S. Dec. 83 Dr. Feldman, Pharmaceutics 33. Hiro Panjabi M.S. May 83 Dr. Feldman, Pharmaceutics 34. T.H. Kuo M.S. May 83 Dr. Lee, Pharmaceutics

D. S-L. Chow

5/9/2012 52

SERVICE ACTIVITIES I. ACADEMIC ADMINISTRATION I-A. Chair of Committees I-A-1. At University Level

1. Chair, Intellectual Property Committee, University of Houston System, September 2007- August 2009; Member, September 2006 – Present.

2. Chair, Review Committee on Dean of College of Natural Sciences and Mathematics, UH,

March - May 1995. 3. Chair, Radiation Safety Committee, UH, September 1987-1988; Member, September

1982-94;

I-A-2. At College Level

1. Chair, Graduate Education Committee, January 2012- August 2014.

2. Chair, College Budget Advisory Council (CBAC), College of Pharmacy (COP), UH, February 2010.

3. Chair, Accreditation Self-study Subcommittee on Financial Resources, COP, UH, June 2009 – March 2011; February 2004 – February 2005.

4. Chair, Faculty Advisory Council (FAC), COP, UH, November, 2007 – August 2010;

Member, September 2005- August 2010; September 1993- 1996.

5. Chair, Selection Committee of Faculty Excellence Awards, COP, UH, March – May 2006.

6. Chair, Faculty Grievance Committee, COP, UH, September 2003 – 2009; Member, 1997- 2009.

7. Chair, Fourth-year Review Committee on tenure-track faculty, Department of Pharmacological and Pharmaceutical Sciences, COP, UH, November, 2001.

8. Chair, Three-year Review Committee on tenure-track faculty, Department of Pharmacological and Pharmaceutical Sciences, COP, UH, November, 2000.

I-B. Member of Committees I-B-1. At University/Texas Medical Center Levels

D. S-L. Chow

5/9/2012 53

1. University of Houston, Faculty Senate, January 2012- August 2014; Budget and Facility Subcommittee, January 2012- August 2014.

2. Dean Search Committee, COP, UH, October 2008 – April 2009; September 1991-June 1992; September 1986-April 1987.

3. Review Committee on Dean of COP, UH, December 2006- April 2007; November-

December 1990.

4. Undergraduate Discovery Advisory Board, Discovery-based Learning Initiative for Quality Enhancement Program (QEP), UH, June 2008- Present.

5. Academic Program Committee for Investiture of UH President Dr. Khator, June – September 2008 (Nominated by UH Faculty Senate).

6. Institutional Animal Care and Use Committee (IACUC), UH, September 1999-August 2002.

7. Health Professional Advisory Committee (HPAC), UH, September 1999- 2002.

8. Chemical Carcinogen Subcommittee, Institutional Biosafety Committee, UT-M.D. Anderson Cancer Center, Texas Medical Center (TMC), September 1996- August 2000.

9. Institutional Biosafety Committee, UT-M.D. Anderson Cancer Center, Texas Medical Center, September 1995- June 2004.

10. Planning Advisory Committee, TMC, April 1991 - January 1994.

11. Student Affairs Advisory Council, TMC, June 1991 - January 1994.

12. Safety Committee, UH, September 1987-1988. I-B-2. At College Level 1. Executive Council, COP, UH, November 2007 – August 2010; February 1991 –

July 1993.

2. Promotion and Tenure Committee, June 2009 – Present; August 2000 – August 2004; 1987-1993.

3. Research Committee, September 2010- present.

4. Graduate Studies Committee, COP, UH, September 2010- present; September 2002 –

August 2004; September 1993-August 2000. 5. Students Affairs Committee, COP, UH, September 2006 – August 2011.

D. S-L. Chow

5/9/2012 54

6. Ad Hoc Committee, Development of Program for Bachelor of Science degree of

Pharmaceutical Sciences (BSPS), COP, UH, October 2005- May 2006. 7. Search Committee for Chair, Department of Pharmacological and Pharmaceutical

Sciences, COP, UH, June - December 2004. 8. Task Force of Steering Committee, Accreditation, COP, UH, June 2009 – March 2011;

February 2004 - February 2005.

9. Education Committee, COP, UH, September 2001- Summer 2003.

10. Post-Tenure Review Committee, COP, UH, July 1999- 2008.

11. Advisory Committee, Pharm.D./Ph.D. program, COP, UH, April 1999 – August 2004.

12. Review Committee on Chair of Department of Pharmacological and Pharmaceutical Sciences, COP, UH, August 1999- January 2000.

13. Accreditation Self-study Subcommittee on Faculty and Staff, COP, UH, October 1993-March 1994; January 1986-February 1988.

14. Honor Appeal Board Committee, COP, UH, November 1989 - January 1990. 15. Curriculum Committee, COP, UH, September 1983-1986. 16. Admissions Committee, COP, UH, January 1982- August 1983.

I-B-3. At Department Level 1. Three-year Review Committee on tenure-track faculty, Department of Pharmacological and Pharmaceutical Sciences, COP, UH, January – October 2011, January – May 2010. 2. Graduate Education Committee, November 2009-Present

3. Search Committee for Faculty, Department of Pharmacological and Pharmaceutical Sciences, COP, UH, September –December 2011; September 2002-August 2007; February 1999- March 2002.

4. Three-year Review Committee on tenure-track faculty, Department of Clinical Sciences

and Administration, COP, UH, June 2008; September 2001.

5. Department Coordinator, United Way Campaign, UH, November-December 1988.

D. S-L. Chow

5/9/2012 55

II. PROFESSIONAL/SOCIETY SERVICES II-A. Reviewing Research Grant Proposals for the Following Programs:

1. Canadian Institutes of Health Research (CIHR)/ GlaxoSmithKline (GSK) Partnered Professorship Review Committee, May 2009.

2. Earmarked Research Grants, Hong Kong Research Grants Council (RGC), March 2, 2009;

March 8, 2012. 3. Pilot proposals from Texas Southern University, Research Center in Minority Institutions

(RCMI) Program, National Center for Research Resources (NCRR), NIH, February 27, 2009

4. Development of a Third Generation Anthrax Vaccine, RFP-NIH-NIAID-DMID-07-05,

NIAID, NIH, January 11-12, 2007

5. Pharmaceutical and Chemical Resources for AIDS Drug Development (PCRADD), Special Emphasis Panel, NIAID, NIH, October 2-3, 2006; Invited back as one of two from initial 19 reviewers for Sources Selection Committee Meeting, March 8, 2007.

6. New Investigator Program (NIP), American Association of College of Pharmacy (AACP),

2005.

7. Phillip Morris External Research Program, November 2002 & 2004.

8. Ad Hoc Reviewer, Small Business Technology Transfer Research (STTR) Program (R41), NIH, June 2000.

9. Contract Proposals to RFP NIH-NAID-DAIDS-00-11, National Institute of Allergy and Infectious Diseases, NIH, February, 2000.

10. Small Grants Program (R03), National Institute of Drug Abuse, NIH, 1997.

11. Program to Enhance External Research (PEER), UH, 1996 & 1998.

12. Earmarked Research Grants, Hong Kong Research Grants Council (RGC), 1996-97.

13. Institute of Space Systems Operations, Area of Drug Delivery, UH, 1994.

14. Biomedical Research Support Grant, UH, 1989-90.

15. Advanced Research Program, UH, 1985-86.

16. Research Initiating Grant, UH, 1984-85, 1986-87, 1991, 1997.

D. S-L. Chow

5/9/2012 56

17. New Research Opportunities Program, UH, 1983-84.

18. Research Enabling Grant, UH, 1982-83, 1983-84. II-B. Program Reviewer for the Following National Meetings:

1. Subcommittee Chair, Screening and Review Committee, PDD, AAPS, 23rd Annual National Meeting, November 2008.

2. Screening and Review Committee, PDD, AAPS, 21st Annual National Meeting,

November 2006.

3. Screening and Review Committee, PDD, AAPS, 19th

Annual National Meeting, November 2004.

4. Screening and Review Committee, PDD, AAPS, 15th

Annual National Meeting, October 2000.

5. Screening and Review Committee, PDD, AAPS, 9th Annual National Meeting, November 1994.

6. Screening and Review Committee, PDD, AAPS, 7th Annual National Meeting, November 1992.

7. Screening and Review Committee, APS 37th National Meeting, October 1984. II-C. Reviewer for the Following Refereed Journals:

1. Editor, British Journal of Pharmacology, May 2009 – Present; Reviewer, 2006 – Present 2. Editorial Board Member, Journal of Drug Development and Industrial Pharmacy, 2000-

Present. 3. International Journal of Pharmaceutics, 1985-Present. 4. Journal of Pharmaceutical Sciences, 1988-Present. 5. Pharmaceutical Research, 1989-Present. 6. European Journal of Pharmaceutics and Biopharmaceutics, 1997-Present 7. International Journal of Pharmaceutical Compounding, 1998-Present 8. Journal of Controlled Release, 2000-Present. 9. PDA Journal of Pharmaceutical Science and Technology, 2003-Present. 10. Nutrition and Cancer, 2003-Present. 11. Journal of Pharmacokinetics and Pharmacodynamics, 2004-Present 12. Toxicology and Applied Pharmacology, 2006-Present 13. Therapeutics and Clinical Risk Management, 2006 – Present 14. Clinical and Experimental Hypertension, 2007-Present 15. J. Chromatograph B, 2008- Present 16. Life Sciences, 2008- Present 17. Molecular Pharmaceutics, 2009- Present

D. S-L. Chow

5/9/2012 57

18. Molecular Imaging and Biology, 2010 - Present 19. Mathematical Biosciences, 1986. 20. ACS Symposium Book, Recent Advances in Controlled Release Technology, 1986. 21. Biopharmaceutical and Drug Disposition, 1985-87.

II-D. External Reviewer for Promotion and Tenure of Other Institutions

1. Department of Emergency Medicine, University of Texas – M.D. Anderson Cancer Center, Houston, TX, December, 2011.

2. Department of Genitourinary Medical Oncology, University of Texas – M.D. Anderson Cancer Center, Houston, TX, December, 2011.

3. Massachusetts College of Pharmacy and Health Sciences, Boston MA, October 2011.

4. College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX,

October 2011.

5. School of Pharmacy, University of Missouri-Kansas, August 2011.

6. Department of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, August 2011.

7. Department of Pediatrics, School of Medicine, Indiana University, June 2011.

4. Department of Pharmaceutical Sciences, Albany College of Pharmacy, Albany, NY,

January 2008.

5. Department of General Internal Medicine, University of Texas – M.D. Anderson Cancer Center, Houston, TX, November, 2005.

6. College of Pharmacy, Western University of Health Sciences, Pomona, CA, April , 2003.

7. College of Pharmacy and Health Sciences, Texas Southern University, Houston, TX,

January 2003.

8. College of Pharmacy, South Carolina University, Columbia, South Carolina, October, 2000.

9. Division of Diagnostic Imaging, University of Texas – M.D. Anderson Cancer Center, Houston, TX, April, 2000.

10. College of Pharmacy and Health Sciences, Mercer University, March 1994.

11. College of Pharmacy, Medical University of South Carolina, February 1993.

D. S-L. Chow

5/9/2012 58

II-E. Review of Books:

1. Basic Clinical Pharmacokinetics, 4th

Ed., M. E. Winters, Lippincott Williams & Wilkins, 2004, (2006).

2. Martin’s Physical Pharmacy and Pharmaceutical Sciences, 5th Edition, Patrick J. Sinko (Ed), Lippincott Williams & Wilkins (2003 & 2004).

3. Applied Pharmacokinetics, 3rd

Ed., W.E. Evans, J.J. Schentag and W.J. Jusko, Lippincott Williams & Wilkins, 1992, for the development of the 4

th Edition of the book (2001).

4. Basic Clinical Pharmacokinetics, 3

rd Ed., M. E. Winters, Lippincott Williams & Wilkins,

1994, for the development of the 4th

Edition of the book (2001).

5. American Journal of Pharmaceutical Education, 53:323-4 (1989), on Controlled Release of Drugs: Polymers and Aggregate Systems, M. Rosoff (Ed.), VCH, 1989".

6. American Journal of Pharmaceutical Education, 52:102 (1988), on

Transdermal Controlled Systemic Medications, Yie W. Chien (Ed.), 1987". II-F. External Examiner for Other Institutions

1. Examiner on Pharmaceutics and Medicinal Chemistry, Pharmacy Program, University of West Indies, Trinidad, May 2009- May 2015.

2. Examiner for dissertation defense, Limin Zhou, Ph.D. supervised by Dr. Joan Z. Zuo,

Chinese University of Hong Kong, August 2008.

3. Examiner for thesis defense, Cindy Anne Bhagwadin, M.S. supervised by Dr. Gopal Pillai, University of West Indies, Trinidad, April 2008.

4. Examiner for dissertation defense, Yuan Gao, Ph.D. supervised by Dr. Albert Chow,

Chinese University of Hong Kong, March 2005. II-G. Reviewer for New Drug Applications

Appointed External Reviewer, Food and Drug Administration (FDA), March 1987 - March 1990.

III. Mentorship for High School Students’ Summer Research

Two high school students, Daniel N. Wang and Daniel Huang, on project of “Scheduling as a factor in combination therapy of a farnesyltransferase inhibitor, manumycin A, with other cell cycle specific chemotherapeutic agents for lung cancer” May – September 2005

D. S-L. Chow

5/9/2012 59

The students won Southwestern Regional Finalists in Siemens Westinghouse Science Competition, November 2005.

IV. Hosting of the visitors organized by International Visitor Program, Institute of International

Education/Southern Region, State Department

Dr. Asakura, Chief of Clinical Trial Consultation in Japan’s Organization of Pharmaceuticals Safety and Research, March 20, 2003, for the purpose of learning about U.S. Pharmaceutics graduate education in the areas of formulation development and regulatory affair for commercialization of products.

V. Consulting V-A. Pharmaceutical Companies or Legal Firms

1. Conrex Pharmaceutical Corp., 1984-1989. 2. Ortho Pharmaceutical Corp., 1988-1989. 3. The Boots Company (USA) Inc., 1988-1991. 4. Allergan Pharmaceuticals Inc., 1989-1991. 5. Greenwich Pharmaceutical Inc., 1989. 6. Sage Pharmaceutical, Inc., 1991-2001 7. Stehlin Foundation for Cancer Research, 1997-Present 8. Chrysalis Biotechnology, 1997. 9. Natural Therapeutics, 1998-2000.

10. Texas Biotechnology Corporation, 2000. 11. Texas Southern University, School of Pharmacy, 2000-Present. 12. Encysive, 2005-2007. 13. Locke Liddell & Sapp, LLP, 2005. 14. Shook, Hardyl & Bacon, LLP, 2005. 15. Cahn Litigation, LLC, 2008.

V-B. Professional consultation with colleagues in other colleges at UH

1. Dr. Chengzhi Cai, Department of Chemistry, on in vivo biocompatibility tests of polymeric coated nanodisc in rat and mouse models for the development as potential drug delivery system, 2007.

2. Dr. Randall Lee, Department of Chemistry, upon request of Intellectual Property

Office of UH, to consult on in vitro evaluations of patented gold cored polymeric nanoparticles for product development, 2006

OTHER TRAININGS

D. S-L. Chow

5/9/2012 60

I. Pharmacy Practice Experience (Pre-registration) A. June-September, 1972 Pharmaceutical production, research and development, Takeda Pharmaceutical Co., (Taiwan) Ltd, Taoyuen, Taiwan. B. January-April 1973 University Hospital Pharmacy, Taipei, Taiwan. II. Wide Spectra of Expertise and Research Training

Extensive backgrounds were established in organic chemistry, physical chemistry and physical pharmacy during my study at O.S.U., and in glucocorticoid and steroid biochemistry while at U.B.C. Experience in research tools involves high-performance liquid chromatography (UV and fluorescence detection), gas liquid chromatography (electron-capture and flame ionization detectors), mass spectrometry, liquid scintillation technique, thin layer chromatography, column chromatography, spectrofluorometry, UV-spectrophotometry, radio-immunoassays, protein assay, DNA assay, data analysis with computer software, such as NONMEM, WINNONLIN, RSTRIP, LAGRAN, Lotus 1-2-3, and Epistat.

III. Additional Training Attended five short courses (1982-2009):

1. Introduction t population pharmacokinetics using NONMEM system and PDx-Pop, by

Dr. Richard Brundage, March 16-18, 2009 2. Advanced methods in pharmacokinetics/pharmacodynamics, University of California,

San Francisco, 1995.

3. Molecular modeling, offered by Institute for Molecular Design, UH, Houston, TX, 1991.

4. Fundamentals of cell culture and quality control, Flow Laboratory, Houston, TX, 1984.

5. Microcapsules Fabrication and Processing, Chemical Engineering, Washington

University, St. Louis, 1983. OTHER RECOGNITIONS

1. Finalist, College of Pharmacy for Faculty Teaching Excellence Award, COP, UH, April 2008

D. S-L. Chow

5/9/2012 61

2. Finalist, College of Pharmacy for Faculty Teaching Excellence Award, COP, UH, April 2007.

3. Certificate of Recognition for 25-year service in COP, UH, May 2006.

4. Certificate of Recognition for 20-year service in COP, UH, May 2001.

5. Nominee, Faculty Excellence Award, COP, UH, February 1999. 6. Nominee by the COP for John and Rebecca Moores’ University Scholars, UH, July

1996.

7. Member of delegation selected to participate in PMA Coordinated Industry Program for Pharmacy Faculty, Pharmaceutical Manufactures Association, August 1983.

8. Career Development Scholarship, Central Campus Committee on the Status of

Women, UH, January 1982.

diana shu-lian chow, ph.d. office address phone & e...

Documents